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ABSTRACT 
 
Testicular Function in Normal and Poor Semen Quality Stallions.  (December 2004) 
Tina Michelle Bryan, B. S., Texas A&M University 
Chair of Advisory Committee:  Dr. Thomas H. Welsh, Jr. 
 
 The chromosomal location of endocrine genes was established, and relationships 
between expression of specific endocrine genes and measures of testis function in normal 
and poor semen quality stallions was assessed.  Consensus primer sequences for 
glucocorticoid receptor (GR) and luteinizing hormone receptor (LHR) were used to 
screen the CHORI-241 equine bacterial artificial chromosome (BAC) library.  The 
identity of PCR-positive BAC clones was confirmed by sequencing.  Verified BACs 
were mapped to horse metaphase chromosome spreads by fluorescence in situ 
hybridization (FISH).  The BACs containing the GR and LHR were localized by FISH to 
ECA 14q16-q21 and ECA15q22-q23, respectively.  In addition to FISH mapping, the 
5000rad horse x hamster radiation hybrid (RH) panel was screened in duplicate.   Two-
point linkage analysis placed GR 0 cR from LEX047, while LHR was 36.67 cR from 
TKY011 on ECA14 and ECA15, respectively.  Total testicular parenchymal weight, 
mean daily sperm production (DSP) per gram parenchyma and mean apoptotic rate 
(406.05 ± 24.33g vs. 180.01 ± 34.41g, 15.29 ± 0.87 vs. 10.24 ± 1.10, 6.70 ± 0.88 vs. 
14.25 ± 1.11, respectively) differed (P<0.05) between normal (n=8) and poor semen 
quality (n=5) stallions.  Also, plasma estradiol and inhibin concentrations were higher 
(P<0.05) in normal stallions than in poor semen quality stallions.  Testicular expression 
iv  
of estrogen receptor beta (ER beta), βB inhibin, prolactin receptor (PRLR), growth 
hormone receptor (GHR) and insulin-like growth factor I receptor (IGF-IR) mRNAs were 
all lower (P<0.05) in poor semen quality stallions than in normal stallions. 
 The BACs and primers developed in this study will facilitate future investigations 
of GR and LHR gene structure in the horse as well as providing a resource for 
physiological investigation of these two genes that are primary regulators of stress 
responsiveness and fertility.  These data add important endocrine genes to the horse 
cytogenetic map.  Also, important hormonal and gene expression changes have been 
identified in poor semen quality stallions for further investigation. 
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CHAPTER I 
INTRODUCTION 
The horse industry in the United States, especially in the state of Texas, has a 
substantial economic impact.  Since many horses in Texas are used for breeding 
purposes, reduced fertility of stallions has a significant adverse economic impact.  
Subfertility is a relatively common condition in stallions.  Although many cases are 
detected by reduced semen quality, the specific cellular/molecular basis for the altered 
testicular function is usually unidentified making precise treatment impossible.  
Research information is needed for identification and treatment of stallion infertility and 
poor semen quality. 
Spermatogenesis and steroidogenesis are critical for fertility of the male animals.  
Breeding soundness exams (BSE) can be used to identify fertility problems associated 
with reproductive organs, mating, sexual behavior and ejaculate quality of stallions.  
However, testing the endocrine system and cell signaling pathways involved in fertility 
and testicular function is not as simple.  Due to the large number of steroids, proteins 
and paracrine/autocrine factors involved in normal spermatogenic and steroidogenic 
activity, there are many areas where fertility problems can occurr.  Environmental 
factors, animal handling and stressors also have a large impact on fertility.  Therefore, 
identification of predictable measures of animal fertility is critical in the horse industry.  
Further research involving cellular/molecular mechanisms would increase our 
__________ 
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knowledge about causes of poor semen quality and would help reduce economic losses 
associated with breeding stallions. 
 
The objectives of this project were to investigate relationships between: 
 1) seminal parameters 
 2) testicular germ cell apoptosis 
 3) circulating hormone concentrations 
 4) gene expression in the testis 
 5) in vitro testis production of testosterone and StAR protein synthesis 
Additionally, our objectives involve tool development for studying stallion 
cellular/molecular signaling in the testis and mapping important endocrine genes in 
horses.  These objectives will help to identify parameters useful for future research in 
understanding stallion fertility. 
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CHAPTER II 
LITERATURE REVIEW 
Horses represent a significant industry in the United States and have a substantial 
economic impact in the state of Texas.  Since many horses in Texas are used for 
breeding purposes, reduced fertility of mares and stallions has a significant adverse 
economic impact on the horse industry.  The impact of stallion subfertility on economic 
loss is magnified over that of mares since stallions may be bred to numerous mares 
during a breeding season.  Subfertility is a relatively common condition in stallions.  
Although many cases are detected by reduced semen quality, the specific 
cellular/molecular basis for the altered testicular function is usually unidentified making 
precise treatment impossible.  Due to high individual animal value, studying the 
molecular basis for altered testicular function is quite difficult.  However, critical 
research information is needed for identification and treatment of stallion infertility and 
poor semen quality.   
Male Spermatogenesis and Steroidogenesis 
The male testes have two major functions, which include production of sperm 
through the process of spermatogenesis and production of male sex hormones through 
steroidogenesis.  Spermatogenesis and steroidogenesis are both necessary for fertility of 
the animal.  Breeding soundness exams (BSE) are used to examine reproductive organs, 
behavior, quantity and quality of ejaculate, and function of the reproductive endocrine 
system (Juhasz et al., 2000).  Due to the high individual value of stallions and the 
relatively high incidence of fertility disorders, there is interest in detection methods for 
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fertility parameters (Juhasz et al., 2000; Varner et al., 2000).  Testicular parameters such 
as daily sperm production (DSP) and DSP per gram of testicular parenchyma, referred to 
as spermatogenic efficiency, are two of the many parameters used to quantitate sperm 
production in the stallion (Senger, 1999).  Hormone measurements are also used to 
evaluate the function of the endocrine system of an animal.  Measuring baseline 
concentrations of reproductive hormones are sometimes useful for identifying hormonal 
imbalances that could be associated with subfertility (Juhasz et al., 2000). 
Normal spermatogenesis is a relatively inefficient process that results in the loss 
of a large number of spermatozoa which do not mature in the adult testis (Clermont, 
1962; Huckins, 1978).  Apoptosis or programmed cell death has been implicated in the 
testis as an essential mechanism for removal of developing germ cells from the 
seminiferous epithelium (Knudson et al., 1995; Rodriguez et al., 1997; Russell et al., 
2002) and has recently been reported in the testis of normal stallions (Heninger et al., 
2004).  Since basal levels of germ cell apoptosis have been identified for stallions with 
normal testes and semen quality, further research evaluating the role of apoptosis in 
stallions with poor semen quality is possible and would add useful information for the 
understanding of molecular mechanisms in the testis. 
 The major factors that control the production of testosterone by the Leydig cells 
and spermatozoa by the seminiferous tubules are the gonadotrophic hormones 
luteinizing hormone (LH) and follicle-stimulating hormone (FSH) (Figure 1).  These two 
hormones are secreted by the anterior pituitary gland under the control of the pulsatile 
secretion of gonadotropin-releasing hormone (GnRH) into the pituitary portal vessels.  
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LH binds to the luteinizing hormone receptor (LHR) to stimulate testosterone production 
and FSH binds the follicle-stimulating hormone receptor (FSHR) to stimulate 
spermatogenesis in the testis.  Secretion of LH and FSH are also controlled by negative 
feedback messages from the testis through the secretion of testosterone and inhibin, 
respectively. 
 
 
 
 
Hypothalamus
Anterior Pituitary
Testis
GnRH
LHFSH
ST LC
 
Figure 1.  Schematic diagram of the hypothalamic-pituitary-testicular (HPT) axis. 
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Normal spermatogenesis is dependent upon a functional hypothalamic-pituitary-
testicular (HPT) axis, which involves classic endocrine actions of gonadotropins, 
feedback mechanisms of steroids and proteins and paracrine/autocrine modulation 
(Roser, 2001).  This includes such hormones as LH, FSH, testosterone, estradiol, inhibin 
and IGF-I as well as many others.  Via a negative feedback mechanism, testosterone 
controls secretion of GnRH, LH and FSH (De Kretser et al., 1995) while supporting 
spermatogenesis and libido.  Also, testicular estrogen appears to play a role in 
reproductive function in the stallion (Thompson and Honey, 1984; Muyan et al., 1993).  
Numerous studies have demonstrated that testosterone and estradiol exert negative 
feedback to inhibit LH secretion and inhibin acts negatively to inhibit FSH secretion (De 
Kretser et al., 1995).  Since all of these hormones create homeostasis in the testis for 
spermatogenesis, information is needed about hormonal changes in poor semen quality.  
Plasma inhibin appears to be a useful indicator of reproductive activity in stallions due to 
a positive correlation between plasma immunoreactive (ir)-inhibin and testicular activity 
(Nagata et al., 1998a).  Motton and Roser (1997) indicate that plasma LH, FSH, estradiol 
and testosterone concentrations are not different between normal and poor semen quality 
stallions, but that LH and FSH were significantly higher and estradiol, testosterone and 
inhibin concentrations were significantly lower in innormal stallions as compared to 
normal and poor semen quality stallions.  Also, Hess and Roser (2001) state that plasma 
IGF-I concentration does not have a direct relationship with declined fertility in stallions.  
Since hormone measurements are a non-invasive test method for fertility and these data 
were from a small population of stallions, further research is warranted to confirm the 
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results cited in the literature and to examine hormonal relationships and testicular 
function in the stallion. 
In Vitro Testicular Culture Systems 
The use of tissue culture methodology has facilitated the understanding of inter-
cellular communication as well as synthesis and secretion of many cellular products.  
Also, culture methods are useful to test specific mechanisms in a more controlled 
atmosphere than in the animal where environment and stressors can impact the results.   
The protein kinase A (PKA) system is considered a cAMP-dependent pathway 
and works by using three components:  1) receptor, 2) a regulatory component (G 
protein) and 3) a catalytic component (adenylate cyclase).  In the PKA system, binding 
of the membrane-bound receptor stimulates the regulatory component, also called the G 
protein and the G protein can be stimulatory (Gs) or inhibitory (Gi).  Stimulation of the 
Gs protein is responsible for activation of adenylate cyclase whereby the biological 
action of the hormone is initiated.  Human chorionic gonadotropin (hCG), produced by 
the chorion of pregnant women, has an amino acid composition and bioactivity very 
similar to that of LH and is free of FSH contamination.  Therefore, hCG is widely used 
for research purposes as a substitute for LH, which uses the PKA system for biological 
action.  Forskolin, a chemical isolated from the roots of the Coleus plant, has proven to 
be a reliable tool for the study of second messenger systems.  Forskolin activates 
adenylate cyclase without the aid of the Gs protein (Seamon and Daly, 1981).  Culturing 
testicular parenchyma allows for the addition of compounds such as hCG, which elicits 
an LH-like response without affecting FSH activity, and forskolin, which activates 
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cAMP directly.  HCG would enable testing the LHR signaling mechanisms in the 
stallion testis.  Addition of forskolin to cultured testicular parenchyma allows testing of 
the second messenger system through activation of adenylate cyclase, which bypasses 
the LH receptor.  Both hCG and forskolin use would initiate steroidogenesis in the 
testicular Leydig cells and stimulate synthesis of testosterone.  The testosterone can be 
assayed by RIA methods to detect changes due to in vitro challenges of testis tissue and 
Leydig cell stimulation.  This is a diagnostic tool to directly test the secretory capacity of 
the Leydig cells (Juhasz et al., 2000).  The sites of LH and forskolin action and the 
pathway of testosterone production are diagramed in Figure 2. 
 Other changes such as gene expression in the testis can be measured to determine 
effects of hormone pathways and second messenger systems on male fertility.  The 
biosynthesis of all steroid hormones begins with the transport of cholesterol from the 
outer mitochondrial membrane to the inner mitochondrial membrane by StAR protein 
(Stocco and Clark, 1996).  Subsequently, the conversion of cholesterol to pregnenolone 
by the cytochrome P450 side-chain cleavage (P450scc) enzyme complex takes place and 
starts the cascade of enzymatic reactions required for testosterone production (Kerban et 
al., 1999).  Previous studies have demonstrated regulation of StAR mRNA with hCG 
treatment (Kerban et al., 1999) which suggests that hCG challenges affect gene 
expression in the testis.  Changes in StAR and P450scc proteins can be measured using 
western blot techniques to analyze differences in expression due to hCG or forskolin 
treatment of testis tissue and to examine relationships with level of testicular function. 
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Figure 2.  Schematic diagram of the activation of Leydig cell steroidogenesis by 
luteinizing hormone (LH), forskolin and (Bu)2cAMP.  Figure abbreviations are as 
follows:  membrane bound receptor (R), stimulatory G protein (Gs), adenylate cyclase 
(AC), cyclic AMP (cAMP), protein kinase A (A-Kinase), dihydroepiandrosterone 
(DHEA) and hydroxysteroid dehydrogenase (HSD). (Modified from French, 1988) 
 10
Gene Expression in the Testis 
The StAR protein mediates the rate-limiting step in steroidogenesis where 
cholesterol is transported to the cholesterol P450scc enzyme.  The expression of StAR 
protein in the stallion testis is essential for steroid hormone production of testosterone, a 
hormone essential for libido and fertility.  A reduction in StAR gene expression would 
likely result in a reduction in steroidogenesis (Leers-Sucheta et al., 1999) and a decrease 
in testosterone production.   
Localization of StAR protein has been demonstrated in ovaries of the mare 
(Watson et al., 2000) but expression patterns of StAR in the stallion testis have not been 
reported.  GR, LHR and StAR gene expression have been demonstrated both in the 
mouse and rat testis, but have not been studied in the stallion.  Controversial results are 
available for expression patterns of the glucocorticoid receptor (GR) in the testis.  
Various techniques and authors have demonstrated expression of GR in some cell types 
of the testis but the results are not in agreement (Weber et al., 2000).  By in situ 
hybridization GR is expected to be present in Leydig cells, spermatogonium, 
macrophages, spermatocytes, round spermatids and sperm.  LHR and StAR expression 
have been demonstrated in the Leydig cells of the testis in the human, mouse, rat, bull 
and pig (Wahlstrom et al., 1983; Sundby et al., 1984; Pollack et al., 1997; Aspden et al., 
1998; Thompson et al., 1999; Garmey et al., 2000; Kotula et al., 2001).  Since the 
Leydig cells are involved in testosterone production in the stallion as in other species, 
the same expression could be found in the stallion. 
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Reproductive competence of an individual depends on appropriate expression of 
the LHR gene.  The LHR is necessary for steroidogenesis and sperm production in males 
(Saez, 1994; Ascoli et al., 2002).  Endogenous and exogenous glucocorticoids may 
modulate libido and fertility by inhibition of genes involved in androgen biosynthesis 
(McKenna et al., 1979; Welsh et al., 1979, 1982; MacAdams et al., 1986).  In particular, 
testicular expression of the GR gene may negatively control expression of the testicular 
LHR gene. 
There are many other genes that have a role in the regulation of steroidogenesis 
and spermatogenesis.  There is a lack of information and understanding of the gene 
expression patterns in the stallion testis as well as their effect on stallion fertility.  Other 
species are often relied upon as surrogate indicators or predictors of gene expression and 
function in the stallion.  This philosophy is a problem due to the unique development 
and maturation of the stallion testis in comparison to other species.  Studies are needed 
to determine gene expression and relationships to testicular function.  This initial study 
focused on genes related to steroid and sperm production:  namely, we studied a) 
receptors for classic pituitary-derived factors such as LHR, follicle-stimulating hormone 
receptor (FSHR), prolactin receptor (PRLR) and growth hormone receptor (GHR); b) 
steroid receptors such as androgen receptor (AR), estrogen receptor (ER) and 
glucocorticoid receptor (GR); c) growth factors such as insulin-like growth factors I and 
II and insulin-like growth factor I receptor (IGF-IR); and d) others such as Steroidogenic 
acute regulatory (StAR) protein and inhibin. 
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Gene Mapping 
This project involved characterizing and gene mapping of the equine 
glucocorticoid receptor (GR) and luteinizing hormone receptor (LHR).  Also, gene 
expression standards were established for GR, LHR and StAR genes in the normal 
stallion testis and the developing stallion testis to allow for future research in 
understanding causes of stallion infertility and poor semen quality problems. 
Two isoforms of GR are formed from one gene by alternative splicing.  GR alpha 
has been identified as the active isoform of GR since it binds ligand in the cell cytoplasm 
and subsequently the complex translocates into the nucleus binding DNA glucocorticoid 
response elements (GREs) and altering the expression of target genes by repression or 
activation of gene transcription.  The GR beta isoform is present in the nucleus of the 
cell and does not bind ligand (Pujols et al., 2002; Schaaf and Cidlowski, 2003).  The 
function of GR beta is not fully understood but is thought to bind GR alpha in certain 
cell types to prevent GR alpha from binding ligand and being activated (Yudt et al., 
2003).  The overexpression of GR beta is associated with pathophysiologic conditions 
due to glucocorticoid resistance (Yudt et al., 2003) because neither the exogenous nor 
endogenous GC can interact with GR alpha due to interference by GR beta. 
The GR mediates the anti-inflammatory actions of GCs.  Therefore, it is of 
paramount importance to understand GR gene expression under physiologic and 
pathophysiologic states (i.e., Cushing’s syndrome and glucocorticoid resistance).  Intra-
synovial administration of GCs (naturally occurring and longer-acting synthetics) is a 
common treatment for noninfectious inflammatory joint injuries unassociated with bony 
 13
or articular fractures.  Therapy of acute neurologic disease and ataxia often includes 
systemic administration of large doses of GCs to relieve inflammation of the spinal cord 
and meninges.  It is important to identify doses that will therapeutically relieve local 
inflammation, without provoking unwanted side effects on immune and reproductive 
functions (Rowland et al., 1998; McKay and Cidlowski, 1999; Schmidt et al., 1999) that 
are manifested by expression of the GR gene and activation of the GR protein. 
Gonadal expression of GR mediates the inhibitory effect of exogenous and 
endogenous glucocorticoids on differentiated reproductive functions.  Analogously, 
adrenal expression of LHR has been linked with development of adrenocortical 
tumorigenesis and overproduction of cortisol, which is characteristic of Cushing’s 
Syndrome (Bielinska et al., 2003; Feelders et al., 2003; Mikola et al., 2003).  The 
availability of species-specific probes will allow a more detailed molecular definition of 
the physiologic and pathophysiologic coupling of the adrenal and gonadal axes. 
One of our objectives was to have primers that would distinguish between the 
hormone binding (GR alpha) and non-hormone binding (GR beta) isoforms of GR in the 
horse.  By distinguishing between the isoforms it allows for a better understanding of 
function as well as confirmation of the presence of both isoforms in the horse.  The 
synteny of GR beta is not conserved across species and is absent in the mouse (Otto et 
al., 1997).  This leads to questions of the physiological significance of the GR beta 
isoform in other species.  Since GR mapped to human chromosome 5, our hypothesis 
was that GR would map to either equine chromosome 14 or 21 (Chowdhary et al., 2003). 
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Compared to the Human Genome Project, limited information is available 
regarding the Equine Genome.  Mining of the Human Genome accelerates the study of 
endocrine and immune system genes in domestic animals including the horse.  
Identification of the chromosomal locations of GR and LHR in the horse allows for 
future research and development of tests for determination of GC excess as in the case of 
Cushing’s syndrome in the horse.  Availability of equine specific probes will allow for 
clarification of LHR role in reproduction and GR isoforms for use in gene expression 
studies of glucocorticoid resistance. 
 By using methods such as seminal parameter measurements, germ cell apoptotic 
rate, circulating hormone concentrations, in vitro testicular parenchyma culture 
techniques and gene expression, the molecular mechanisms of testicular function might 
be better evaluated.  The objectives of this project were to investigate relationships 
between: 
 1) seminal parameters 
 2) testicular germ cell apoptosis 
 3) circulating hormone concentrations 
 4) gene expression in the testis 
 5) in vitro testis production of testosterone and StAR protein synthesis 
Additionally, our objectives involve tool development for studying stallion 
cellular/molecular signaling in the testis and mapping important endocrine genes in 
horses.  These objectives will help to identify parameters useful for future research in 
understanding stallion fertility. 
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CHAPTER III 
DEVELOPMENT OF MOLECULAR TOOLS TO STUDY GR, LHR, AND StAR 
PROTEIN* 
Introduction 
Characterization of the equine genome through the construction of dense gene 
maps will markedly facilitate investigation of physiologic processes.  Relative to the 
mouse, human and bovine genomes, far fewer genes have been positioned on the equine 
gene map and only a very few of these are associated with endocrine or immune 
function.  The availability of the first generation whole genome radiation hybrid map for 
the horse is a significant recent advance (Chowdhary et al., 2002).  Given the paucity of 
genes from the endocrine axes that have been mapped in horse, we have focused on loci 
that will be of use in physiological studies.  Herein, we describe the chromosomal 
localization of nuclear receptor subfamily 3, group C, member 1 (glucocorticoid 
receptor; GR also known as NR3C1, GCR or GRL), luteinizing 
hormone/choriogonadotropin receptor (LHR, also known as LHCGR, LCGR and LGR2) 
and steroidogenic acute regulatory protein (StAR).  The proteins derived from the GR, 
LHR and StAR genes are pivotal regulators of adrenal and gonadal function, respectively. 
GR plays a critical role in mediating physiologic, pathologic and therapeutic 
actions of glucocorticoids (GCs; Schaaf and Cidlowski, 2002). GCs such as cortisol and  
____________ 
*Reprinted with permission from “Chromosomal Localization of Equine Glucocortiocid 
Receptor (NR3C1) and Luteinizing Hormone Receptor (LHCGR) Genes by Fluorescence 
In Situ Hybridization and Radiation Hybrid Mapping” by T. M. Bryan, 2004.  Animal 
Genetics (accepted). 
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corticosterone are a vital class of steroid hormones that regulate protein, fat and 
carbohydrate metabolism as well as homeostasis. GCs are potent suppressors of immune 
system response and inflammation.  Natural and synthetic forms of GCs have been used 
for over fifty years for therapeutic intervention in a broad range of autoimmune and 
inflammatory disorders.  These biologic actions of GCs are executed via the GR protein 
thus GR gene expression is vital to sustaining health of an individual (Yudt and 
Cidlowski, 2002). 
Reproductive competence of an individual as well as survival of a species 
depends on appropriate expression of the LHR and StAR genes. LHR is necessary for 
steroidogenesis in males and females, sperm production in males and ovum maturation 
in females (Saez, 1994; Ascoli et al., 2002; Saint-Dizier et al., 2003). Endogenous and 
exogenous GCs may modulate libido and fertility by inhibition of genes involved in 
androgen biosynthesis (McKenna et al., 1979; Welsh et al., 1979, 1982; MacAdams et 
al., 1986).  In particular, testicular expression of the GR gene may negatively control 
expression of the testicular LHR gene.  StAR protein mediates the rate-limiting step of 
steroidogenesis by the transfer of cholesterol from the outer to the inner mitochondrial 
membrane of the testis (Stocco and Clark, 1996).  Therefore, appropriate StAR gene 
expression is critical for the continual production of steroids such as testosterone in the 
testis. 
GR has been mapped to human chromosome 5 (Gehring et al., 1985), mouse 
chromosome 18 (Francke and Gehring, 1980) and rat chromosome 18 (Goldner-Sauve et 
al., 1991).  To date, GR has also been identified in the pig and guinea pig but has not 
 17
been mapped yet (http://iowa.thearkdb.org/).  LHR is encoded by a single gene on 
human chromosome 2p21, mouse chromosome 17, rat chromosome 6 and sheep 
chromosome 3 (Rousseau-Merck et al., 1990; Ascoli et al., 2002; 
http://iowa.thearkdb.org/).  StAR has been mapped to human chromosome 8, mouse 
chromosome 8, rat chromosome 16 and cattle chromosome 27 (Sugawara et al., 1995; 
Yuan et al., 1999; Sonstegard et al., 2000; Bonne et al., 2002).  Based on these data, we 
hypothesized that GR would map to either equine chromosome 14 or 21, LHR would 
localize to either equine chromosome 15 or 18 and StAR would map to equine 
chromosome 9 (Chowdhary et al., 2003).  The objective of this mapping study is to add 
important endocrine genes to the equine chromosome map.  This would allow future 
genomics investigation of the placement of endocrine genes and inheritance. 
Materials and Methods 
Primer Design and PCR Conditions 
Consensus primer sequences for GR and LHR are listed in Table 1.  Three primer 
sets for GR were designed in exons 2, 9A and 9B to facilitate future studies on 
alternative splicing of equine GR (Pujols et al., 2002).  GR primers were designed by 
alignment of human (Accession X03348), mouse (Accession NW_000134) and rat 
(Accession NW_043169) genomic vs. mRNA sequences using ClustalX (ClustalX 1.81; 
http://bess.u-strasbg.fr/BioInfo/ClustalX/Top.html).  Likewise, human (Accession 
S57793), mouse (Accession M81310), rat (Accession L23500), cattle (Accession 
AF491303) and sheep (Accession L36329) LHR sequences were aligned (Figure 3).  
PCR conditions for each primer pair were optimized using stallion and hamster genomic 
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DNA as a template.  These primers were used subsequently to screen DNA pools from 
segment 1 of the CHORI-241 equine BAC library and for RH mapping. 
BAC Library Screening 
The Texas A&M University equine BAC library was assembled using the 
CHORI-241 equine BAC library from Pieter J. de Jong (Oakland, CA).  BAC superpools 
were made by combining DNA from each well of a 384-well plate into a single-plate 
pool.  Then eight single-plate DNA pools were combined to make a superpool (Figure 
4).  First, 24 superpools of BAC DNA each representing 8x384 plates were screened.  
Second, the 8 plate pools corresponding to positive superpools were screened (Figure 5).  
Once a positive plate was identified, row and column pools were prepared as described 
by Schibler et al. (1998).  Briefly, 50 µl aliquots of BAC clones from overnight cultures 
were pooled by row and column.  After centrifugation at 3000g, bacterial pellets were 
resuspended in 1ml TE with 1µl used directly as template for PCR.  Addresses of PCR-
positive BACs were denoted as the intersection of rows and columns (Figure 5).  PCR 
products generated from positive BAC clones were confirmed by sequence analysis 
using BigDye v2 terminator chemistry (Applied Biosystems, Foster City, CA) prior to 
mapping.   
Fluorescence In Situ Hybridization (FISH) Mapping 
Sequence verified BACs were mapped to horse metaphase chromosome spreads 
using fluorescence in situ hybridization (FISH; see Appendix A for protocol), as 
 Table 1.  Primer design, fluorescence in situ hybridization and radiation hybrid mapping results for glucocorticoid receptor 
(GR) and luteinizing hormone receptor (LHR). 
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  Gene (primer) MgCl2 
(mM) 
Annealing 
Temp. 
Equine 
FISH 
Results 
HSA Closest
RH 
marker 
LOD 
Score 
Distance 
(cR) 
Glucocorticoid Receptor alpha (GRa)  
(for:  5’ CCTTTCTGTGTGCACCTTACC 3’;  
rev:  5’ TCCATCARCATTTCTTTGACC 3’) 
2.0  51.5°C ECA  
14q16-q21 
HSA5   LEX047 3.0 0
Glucocorticoid Receptor beta (GRb)  
(for:  5’ GGCTGTATGAAAATACCCTCC 3’; 
rev:  5’ CCATATTTGGCATTGCTGTA 3’) 
3.0  53.2°C ECA  
14q16-q21 
HSA5    LEX047 3.0 0
Glucocorticoid Receptor exon 2 (GR)  
(for:  5’ GAAAGCATTGCAAACCTCAA 3’;  
rev:  5’ TCTGTTTTCACTTGGGGCA 3’) 
3.0  60.0°C ECA  
14q16-q21 
HSA5    LEX047 3.0 0
Luteinizing Hormone Receptor (LHR)  
(for:  5’ GCCATAGACTGGCAGACAGG 3’;  
rev:  5’ AGGCAGCYGAGATGGCAAA 3’) 
1.5  60.0°C ECA  
15q22-q23 
HSA2    TKY011 3.0 36.67
 
 
 
 
  
LHR sense primer
LHR antisense primer
 
Figure 3.  Multiple species sequence alignment of human, mouse, rat, cattle and sheep luteinizing hormone receptor 
(LHR) sequences from GenBank.  Sequence similarity was used to identify conserved regions for primer design. 
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BAC DNA Pools 
Microtitre plates each containing 96 BAC clones 
      1                  2                  3                   4                 5                  6                   7                 8 
 
 
 
 
 
Single-plate 
DNA pools  
 
 
 
 
 
Super-pool DNA from 8 single pools  
Figure 4.  Bacterial artificial chromosome (BAC) clone pooling scheme for the TAMU library. 
  Super-pools:   1     2     3     4     5     6     7    8     9    10   11   12   13   14  15   16   17   18
 Single-pools:       1      9     17    25    33    41    49    57    65    73     81    89    97  105  113  121  129  137 
                             8     16    24    32    40    48    56    64    72    80     88    96  104  112  120  128  136  144 
 
  3     D
 19   20  21   22   23   24
145  153 161  169  177  
152  160 168  176  184  
185
190
 41    42    43   44    45    46    47    48
Step 3:  Screen row and 
column pools to identify 
single well location 
Step 2:  Screen 
single-pool DNA
Step 1:  Screen 
super-pool DNA 
Figure 5. PCR-based method for screening equine BAC library pools.  Positive PCR products are shown as gel lanes.
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described earlier (Chowdhary et al., 2002). Briefly, ~1ug probes were biotin-labeled by 
nick translation according to the manufacturer’s instructions (BioNick Labeling System, 
Invitrogen Corp., Carlsbad, CA). The probe was mixed with hybridization solution (2 x 
SSC, 10% Dextran sulphate & 50% formamide) and applied to metaphase spreads at a 
final concentration of 20 ng/ul. Details on hybridization, washing and analysis are 
described elsewhere (Chowdhary et al., 2003).  
Radiation Hybrid (RH) Mapping 
Duplicate RH typing (see Appendix B for protocol) on the 5000rad horse x 
hamster RH panel was carried out as described by Chowdhary et al. (2002, 2003). Two-
point linkage analysis with the markers reported in the first generation RH map 
(Chowdhary et al., 2003) was performed as per instructions available at 
http://equine.cvm.tamu.edu/cgi-bin/ecarhmapper.cgi.  Marker information, PCR 
conditions and RH mapping results are summarized in Table 1. 
Results 
GR exon 2 primers identified three positive BAC superpools (13, 17, & 24).  
Singlepools 97, 99 & 131 were identified for further PCR analysis.  BACs 097-B1, 099-
H1 & 131-C16 were identified as clones containing GR exon 2.  GR exon 9A primers 
identified two positive BAC superpools (6 & 17).  Screening singlepools using exon 9A 
primers identified one positive (45) for row and column testing.  The BAC 045-D15 was 
identified as a clone containing GR exon 9A.  LHR primers identified two positive BAC 
superpools (2 & 14).  Singlepools 15 and 107 each contained a positive PCR product 
using LHR primers and BAC 015-N8 was confirmed. 
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PCR products generated using BAC DNA as template were verified by sequencing prior 
to mapping.  The GR exon 2 PCR product (Figures 6 and 7) (Accession AY392091, 342 
bp:  PCR product used for identity comparison with human; Accession AY394747, 461 
bp:  Cloned product) shared 91% identity with the human genomic sequence for GR.  A 
deletion was present in the equine coding sequence eliminating Lys-Leu at amino acid 
182-183.  Also, there were ten predicted amino acid substitutions in the PCR product for 
exon 2.  The partial sequence for equine GR exon 9A (Figures 8 and 9) (Accession 
AY392092, 330 bp:  PCR product used for identity comparison with human; Accession 
AY550008, 355 bp:  Cloning product) shared 97% identity with the corresponding 
human genomic sequence.  A five-nucleotide deletion in the equine sequence was 1288 
bases from the human exon 9A stop codon.  The equine PCR product (Accession 
AY392093, 361 bp:  PCR product used for identity comparison with human; Accession 
AY394748, 493 bp:  Cloning product) for LHR (Figures 10 and 11) corresponded to the 
human eleventh exon predicted by NCBI Model Maker 
(http://www.ncbi.nlm.nih.gov/mapview/modelmaker.cgi?contig=NT_022184.13&gene=
LHCGR&lid=3973).  There was 92% identity between the horse and human genomic 
sequences.  There were eleven predicted amino acid substitutions in the LHR PCR 
product for the horse. 
BACs containing GR exon 9A and exon 9B were both localized by FISH to ECA 
14q16-q21 (Figure 12).  RH analysis (Figure 13) assigned the marker to the same 
chromosome in close vicinity to LEX047 (0 cR distance between the GR & LEX047; 
odds 1:1000 or LOD 3). The location was in agreement with previous observations 
showing correspondence between ECA14 and HSA5 (Chowdhary et al., 2003).  
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 Equine GR exon 2 PCR product CHORI_241-131-C16 (342bp) AY392091: 
TGTTTCTGCTGCCCCCACAGAGAAGGAGTTTCCAAAAACTCACTCTGAT
GTCTTCAGAACAGCAAAATCTGAAGGGCCAGACTGGCACCAGCAGAG
AATGTGTATACCACAGACCAAAGAACCTTTGACATTTTGCCGGATTTG
GTTTTCTTCTGGGTCCCCAAGTAAAGAGACGAATGAGAGTCCTTGGAG
CAGACCTCTTGATAGATGAAAACTGTCTGCTTTCTCCTTTGGCAGGAGA
ATGATTCATTCCTTTTGGAAGGAAACTCGAATGAAGACTATAAGCCTC
GTTTTACCGGATGCTAAACCTAAAATTAAGGATAATGGA 
anslated Equine GR exon 2: 
SAAPTEKEFPKTHSDVSSEQQNLKGQTGTSRGNVYTTDQRTFDILPDLEFS
SPSKETNESPWRADLLIDENCLLSPLAGEDDSFLLEGNSNEDYKPLVLPDA
KIKDNG Figure 6.  Equine glucocorticoid receptor (GR) exon 2 PCR product sequence 
392091) and translated protein sequence submitted to GenBank. 
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Equine GR exon 2 (TA cloned into PCR2.1) (461 bp) AY394747: 
GAAAGCATTGCAAACCTCAATAGGTCGACCAGTGTTCCAGAGAACCCCAA
GAGTTCAGCATCCGTTGCTGTTTCTGCTGCCCCCACAGAGAAGGAGTTTCC
AAAAACTCACTCTGATGTGTCTTCAGAACAGCAAAATCTGAAGGGCCAGA
CTGGCACCAGCAGAGGCAATGTGTATACCACAGACCAAAGAACCTTTGAC
ATTTTGCCGGATTTGGAGTTTTCTTCTGGGTCCCCAAGTAAAGAGACGAAT
GAGAGTCCTTGGAGAGCAGACCTCTTGATAGATGAAAACTGTCTGCTTTCT
CCTTTGGCAGGAGAGGATGATTCATTCCTTTTGGAAGGAAACTCGAATGA
AGACTATAAGCCTCTCGTTTTACCGGATGCTAAACCTAAAATTAAGGATA
ATGGAGATCTGACCTTATCAAGCCCCAACAGTGTGCCACTGCCCCAAGTG
AAAACAGA 
Translated GR exon 2: 
ESIANLNRSTSVPENPKSSASVAVSAAPTEKEFPKTHSDVSSEQQNLKGQTGTS
RGNVYTTDQRTFDILPDLEFSSGSPSKETNESPWRADLLIDENCLLSPLAGEDD
SFLLEGNSNEDYKPLFYRMLNLKLRIMEIPYQAPTVCHCPKKQX 
Figure 7.  Equine glucocorticoid receptor (GR) exon 2 cloned product sequence 
(AY394747) and translated protein sequence submitted to GenBank. 
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 Equine GR exon 9A PCR product CHORI_241-045-D15 (330bp) AY392092: 
CCTTACCAACTTTCTGTAAACTCAAAACATATTTACTAAGCCACAAGAA
TTTGATTTCTATTCAAGGTGGCCAAATTATTTGTGTAACAGAAAACTGAA
ATCTAATATTAAAAATATGAAACTTCTAATATATTTTTATATTTAGTTAT
GTTTCAGATATATATCATATTGGTATTCACTAATCTGGGAAGGGAAGGG
TACTGCAGCTTTACATGCAATTTATTAAAATGACTGTAAAATAGCTTGTA
AGTGTAAAATAAGAATGATTTTTAGATGAGATTGTTTTATCATGACATGT
ATATATTTTTTGTAGGGGTCAAAGA Figure 8.  Equine glucocorticoid receptor (GR) exon 9A PCR product sequence 
392092) submitted to GenBank. 
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Equine GR alpha (TA cloned in PCR2.1) (355  bp) AY550008: 
CCTTTCTGTGTGCACCTTACCAACTTTCTGTAAACTCAAAACATATTTACT
AAGCCACAAGAAATTTGATTTCTATTCAAGGTGGCCAAATTATTTGTGTAA
CAGAAAACTGAAAATCTAATATTAAAAATATGAAACTTCTAATATATTTTT
ATATTTAGTTATAGTTTCAGATATATATCATATTGGTATTCACTAATCTGG
GAAGGGAAGGGCTACTGCAGCTTTACATGCAATTTATTAAAATGACTGTA
AAATAGCTTGTATAGTGTAAAATAAGAATGATTTTTAGATGAGATTGTTTT
ATCATGACATGTTATATATTTTTTGTAGGGGTCAAAGAAATGCTGATGGA 
Figure 9.  Equine glucocorticoid receptor (GR) exon 9A cloned product sequence 
(AY550008) submitted to GenBank.  
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Equine LHR PCR product CHORI_241-015-N8 (361 bp) AY392093: 
ACTTTCTGTCTACACCCTCACAGTCATCACACTAGAAAGATGGCACACCAT
CACCTATGCTATTCAGCTGGACCAAAAACTACGATTAAGACATGCCATTC
CAATTATGCTTGGAGGATGGCTCTTTTCTACTCTAATTGCTATGTTGCCCCT
TGTGGGTGTCAGCAATTACAGGAAGGTCAGTATTTGCCTCCCCATGGATAT
AGAAACCACTCTCTCACAAGTCTACATATTAACCATCCTGATACTCAATGT
GGTAGCCTTCTTCATCATTTGTGCTTGCTACATTAACATTTATTTTGCAGTT
CAAAATCCACAACTGATAGCTACCAGCAAAGACACAAAGATTGCTAAGA
AAATG 
Translated Equine LHR: 
LSVYTLTVITLERWHTITYAIQLDQKLRLRHAIPIMLGGWLFSTLIAMLPLVGV
SNYRKVSICLPMDIETTLSQVYILTILILNVVAFFIICACYINIYFAVQNPQLIATS
KDTKIAKKM 
Figure 10.  Equine luteinizing hormone receptor (LHR) PCR product sequence 
(AY392093) and translated protein sequence submitted to GenBank. 
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 Equine LHR (TA cloned in PCR2.1) (493 bp) AY394748: 
TGAGATGGCAAAAAAAGAGATAGGTGCCATGCAGGTGAAATC
ATGAGGACTGCCATTTTCTTAGCAATCTTTGTGTCTTTGTTGGT
AGTTGTGGATTTTGAACTGCAAAATAAATTTTAATGTAGCAAGC
ATGAAGAAGGCTACCACATTGAGTATCAGGATGGTTAATATGT
TGAGAGAGTGGTTTCTATATCCATGGGGAGGCAAATACTGACC
ATTGCTGACACCCACAAGGGGCAACATAGCAATTAGAGTAGA
CATCCTCCAAGCATAATTGGAATGGCATGTCTTAATCGTAGTTT
GCTGAATAGCATAGGTGATGGTGTGCCATCTTTCTAGTGTGAT
AGGGTGTAGACAGAAAGTTCACTTGCAAATACAGTGAAAAAGC
ACTACACCCACTCCCTGTCTGCCAGTCTATGGC  11.  Equine luteinizing hormone receptor (LHR) cloned product sequence 
submitted to GenBank. 
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Figure 12.  Fluorescence in situ hybridization (FISH) with BACs containing the 
equine glucocorticoid receptor (NR3C1) exon 9A (panel A) and luteinizing hormone 
receptor (LHCGR; panel C) on horse metaphase chromosome spreads.  G-banded 
ideograms of ECA14 (panel B) and ECA15 (panel D) show location of the NR3C1 and 
LHCGR genes, respectively, in relation to the recently published cytogenetic map 
(Chowdhary et al., 2003). 
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Figure 13.  Radiation Hybrid (RH) mapping  of the glucocorticoid receptor (GR) exon 2.  Two point analysis verifies the 
presence of GR on equine chromosome 14 (ECA14). 
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The LHR-containing BAC was mapped by FISH to ECA15q22-q23 (Figure 12). 
At odds 1:1000 or LOD 3, RH analysis placed LHR at 36.67 cR from TKY011.  Our 
findings concur with earlier observations that indicate homology between ECA15 and 
HSA2 (Rousseau-Merck et al., 1990; Chowdhary et al., 2003). 
The BAC containing StAR protein needs to be isolated from the equine BAC 
library so that FISH mapping can be performed.  This work was planned but due to 
schedule conflicts and equipment problems the results are still unavailable.  Chromosome 
mapping of StAR protein will be performed in the future using FISH mapping and RH 
mapping techniques. 
Discussion 
Compared to the investigation of the human genome, limited information is 
available regarding the equine genome.  Mining information from the human genome 
will accelerate the study of endocrine and immune system genes in domestic animals 
including the horse.  In humans and rats, two isoforms of GR are formed from one gene 
by alternative splicing.  These two isoforms share the first eight exons whereas the ninth 
exon amino acid sequence distinguishes them (Yudt and Cidlowski, 2002).  GR alpha 
expression of target genes is altered by repression or activation of gene transcription.  GR 
alpha has been identified as the active isoform since it binds ligand in the cell cytoplasm, 
dimerizes and subsequently the complex translocates into the nucleus and binds DNA 
glucocorticoid response elements (GREs).  GR beta is present in the nucleus of the cell 
and does not bind ligand (Schaaf and Cidlowski, 2003).  The function of GR beta is not 
fully understood but is thought to dimerize with GR alpha in certain cell types to prevent 
GR alpha from binding ligand and being activated (Yudt et al., 2003).  Overexpression of 
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GR beta is associated with pathophysiologic conditions, which result in glucocorticoid 
resistance (Yudt et al., 2003) because neither the exogenous nor endogenous GC can 
interact with GR alpha due to interference by GR beta.  Equine GR beta (also known as 
GR exon 9B) has also been cloned (Figure 14) and the sequence was submitted to 
GenBank (Accession AY550007, 444 bp:  Cloning product) so that further research can 
be performed to elucidate the function of this GR isoform. 
Although the mouse GR homolog shares the same gene structure, the alternative 
splicing event does not occur and GR beta is absent (Otto et al., 1997). This leads to 
questions of the physiological significance of the GR beta isoform in other species.  In 
this study, BACs that shared sequence similarity with GR exons 9A and 9B were 
recovered and they co-localized to ECA 14q16-21.  This suggests that as in other species 
there is a single GR gene and the structural organization of equine GR is similar to that of 
human, rat and mouse.  BACs from this study will be useful for further characterization 
of equine GR.  Primers were specifically chosen in exons 2, 9A and 9B to facilitate future 
investigations of alternative splicing of equine GR to verify the existence of the GR beta 
isoform in the horse.  Comparison of the equine GR sequence to the human GR sequence 
shows a high level of conservation between horse and human.   Similarly, equine LHR 
and human LHR are highly conserved.  The eleventh exon of LHR is the gene region 
involved in activation of G-proteins for signal transduction (Ascoli et al., 2002).  Since 
the equine LHR PCR product (AY392093) in our study hybridizes this region of the gene, 
tools are available to evaluate mRNA expression of LHR under physiologic and 
pathophysiologic conditions. 
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Equine GR beta (TA cloned in PCR2.1) (444 bp) AY550007: 
GGCTGTATGAAAATACCCTCCTCAAATAACTTGCTTAACTACATATAGATT
CAAGTGTGTCAATATTCTATTTTGTATATTAAACAAATGCTATATAATGGG
GACAAATCTATATTATACTGTGTATGGATGGCATTATTAAGAAGCTTTTTC
ATTATTTTTTATCACAGTAATTTTAAAATGTGTGAAAATTAAAACCAGTGA
CTCCTGTTTAAAAATAAAAGTTGTAGTTTTTTATTCATGCTAAATAATAAT
CTGTAGTAAAAAAAAAAAAAAAAATGTCTTTTTACCTACGCAGTGAAATG
TCAGATTGTAAAATCTTGTGTGGAAACGTTTAACTTTTATTTTTCATTTAAA
TTTGCTGTTCTGGTATTACCAAACCACACATTTGTACTGAATTGGCAGTAA
ATGTTAGTTAGCCATTTACAGCAATGCCAAATATGG 
Figure 14.  Equine glucocorticoid receptor (GR) exon 9B cloned product 
sequence (AY550007) submitted to GenBank.  
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Two forms of equine StAR that only differ in the length of their 3’ untranslated 
region (3’ UTR) have been identified (Kerban et al., 1999).  The open reading frame 
(ORF) encodes a 285-amino acid protein that is 86-90% identical to StAR of other 
species characterized to date (Kerban et al., 1999).  StAR is a phosphoprotein synthesized 
in the cytosol as a short-lived 37-kDa precursor that is processed into more stable 30-kDa 
proteins after mitochondrial import (Epstein and Orme-Johnson, 1991; Stocco and 
Sodeman, 1991; King et al., 1995).  The 37-kDa form of StAR protein is believed to 
represent the active form of StAR involved in moving cholesterol across mitochondrial 
membranes for steroid hormone biosynthesis (Stocco and Clark, 1996). 
GR mediates the anti-inflammatory actions of GCs.  Therefore, it is of paramount 
importance to understand GR gene expression under physiologic and pathophysiologic 
states (i.e., Cushing’s syndrome and glucocorticoid resistance).  Systemic or intra-
synovial administration of GCs (naturally occurring and longer-acting synthetics) is a 
common treatment for noninfectious inflammatory joint injuries unassociated with bony 
or articular fractures.  Therapy for acute neurologic disease and ataxia often includes 
systemic administration of large doses of GCs to relieve inflammation of the spinal cord 
and meninges.  It is important to identify doses that will therapeutically relieve local 
inflammation, without provoking unwanted side-effects on immune and reproductive 
functions (Rowland et al., 1998; McKay and Cidlowski, 1999; Schmidt et al., 1999) that 
are manifested by expression of the GR gene and activation of the GR protein. 
Gonadal expression of GR mediates the inhibitory effect of exogenous and 
endogenous glucocorticoids on differentiated reproductive functions.  Analogously, 
adrenal expression of LHR has been linked with development of adrenocortical 
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tumorigenesis and overproduction of cortisol, which is characteristic of Cushing’s 
Syndrome (Bielinska et al., 2003; Feelders et al., 2003; Mikola et al., 2003).  The 
availability of species-specific probes will allow a more detailed molecular definition of 
the physiologic and pathophysiologic coupling of the adrenal and gonadal axes. 
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CHAPTER IV 
GENE EXPRESSION IN THE TESTIS OF NORMAL AND POOR SEMEN 
QUALITY STALLIONS 
Introduction 
 Many testicular genes have a role in the regulation of steroidogenesis and 
spermatogenesis.  However, there is a lack of information and understanding of the gene 
expression patterns in the stallion testis as well as their affect on stallion fertility.  Other 
species are often relied upon as surrogate indicators or predictors of gene expression and 
function in the stallion.  This philosophy is a problem due to the unique development and 
maturation of the stallion testis in comparison to other species.  Studies are needed to 
determine gene expression, testicular function and fertility of the stallion testis.  This 
initial study focused on genes related to steroid and sperm production:  namely, we 
studied a) receptors for classic pituitary-derived factors such as LHR, follicle-stimulating 
hormone receptor (FSHR), prolactin receptor (PRLR) and growth hormone receptor 
(GHR); b) steroid receptors such as androgen receptor (AR), estrogen receptor (ER) and 
glucocorticoid receptor (GR); c) growth factors such as insulin-like growth factors I and 
II and insulin-like growth factor I receptor (IGF-IR); and d) others such as the 
steroidogenic acute regulatory (StAR) protein and inhibin. 
 The major factors that control the production of testosterone by the Leydig cells 
and spermatozoa by the seminiferous tubules are the gonadotrophic hormones luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH).  These two hormones are 
secreted by the anterior pituitary gland under the control of pulsatile secretion of 
gonadotrophin-releasing hormone (GnRH) into the pituitary portal vessels.  The secretion 
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of FSH and LH is also controlled by negative feedback messages from the testis through 
the secretion of testosterone and inhibin.  FSH appears to have a role in the maintenance 
of spermatogenesis through follicle-stimulating hormone receptors (FSHR) on the 
seminiferous tubules (Means and Vaitukaitis, 1972), Sertoli cells and spermatogonia 
(Orth and Christensen, 1977, 1978; Baccetti et al., 1998).  LH acts through the presence 
of luteinizing hormone receptors (LHR) on the surface of Leydig cells (De Kretser et al., 
1971) to stimulate the production of testosterone, the androgen that is required for 
seminiferous tubule function. 
 Controversy still exists regarding the roles of androgens and estrogens in the 
testis.  Androgens play a crucial role in the development of male reproductive organs and 
are needed for puberty, male fertility and male sexual function (Dohle et al., 2003).  
Androgen receptors (AR) have been localized to Sertoli cells, Leydig cells and 
peritubular cells (Mulder et al., 1975; Sanborn et al., 1977; Verhoeven, 1980; Namiki et 
al., 1991; Nagata et al., 1998b).  Sertoli cell-selective knockout mice have been used to 
demonstrate that the AR in the Sertoli cell is an absolute requirement for androgen 
maintenance of complete spermatogenesis (De Gendt et al., 2004).  The important role of 
estrogens in females in physiological and pathological processes is well accepted.  Recent 
evidence demonstrating the importance of estrogens in male reproductive physiology has 
complicated the division between genders with reference to importance of androgens in 
males.  Both estrogen receptor alpha (ER alpha) and estrogen receptor beta (ER beta) 
isoforms have been detected in the testis (Denger et al, 2001; Makinen et al., 2001; Mowa 
and Iwanaga, 2001).  ER alpha is localized to Leydig cells, round spermatocytes and 
spermatids (Pelletier et al., 2000), while ER beta was detected in Sertoli cells and round 
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spermatocytes (Shughrue et al., 1998).  Since ER alpha knockout mice suffer from 
testicular atrophy and infertility, estrogen is vital for normal testicular function (Mueller 
and Korach, 2001).  While ER alpha knockout mice are completely infertile, ER beta 
knockout mice appear to heave no compromised fertility (Couse et al., 2001).  The 
importance of ER alpha and ER beta in the testis is still unknown and needs further 
investigation. 
 Inhibin is involved in a) the negative feedback mechanism inhibiting secretion of 
FSH by the anterior pituitary as well as b) paracrine regulation of testicular function 
(Marchetti et al., 2003).  Both inhibin alpha and beta B forms appear to be involved in 
spermatogenesis and paracrine/autocrine regulation of androgen production (Kaipia et al., 
1994; Klaij et al., 1994).  Inhibin alpha and beta subunits have been detected in Leydig 
cells and Sertoli cells of the horse testis (Fujimura et al., 1998; Nagata et al., 1998a).  The 
inhibin beta B appears to be the rate-limiting factor in the production of bioactive inhibin 
in the testis (Klaij et al., 1992). 
 There are many other testicular genes that have roles in the regulation of 
steroidogenesis and spermatogenesis.  Steroidogenic acute regulatory (StAR) protein has 
been detected in the Leydig cells of the testis and is required for the transport of 
cholesterol from the outer to the inner mitochondrial membrane for steroid biosynthesis 
(Pollack et al., 1997).  The glucocorticoid receptor (GR) has also been identified in 
Leydig cells, Sertoli cells and germ cells indicating a role in steroidogenesis and 
spermatogenesis (Weber et al., 2000).  The prolactin receptor (PRLR) has been detected 
in Leydig cells, Sertoli cells and various stages of spermatogenesis (Hondo et al., 1995; 
Zhang et al., 1995; Jabbour and Lincoln, 1999).  The expression of PRLR was 
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hormonally regulated by inhibiting FSH (Guillaumot and Benahmed, 1999), which 
indicates a role in spermatogenesis.  However, the fertility of PRLR knockout mice was 
unaffected indicating that the absence of PRL signaling is not detrimental to male 
testicular function and fertility (Binart et al., 2003). 
 Growth factors are also thought to play an important role in the paracrine and 
autocrine control of testicular function (Cailleau et al., 1990; Moore and Morris, 1993; 
Chandrashekar et al., 2001).  Growth hormone receptors (GHR) have been detected in 
Leydig and Sertoli cells of the testis (Lobie et al., 1990).  GHR knockout mice had 
reduced fertility and altered testicular function (Chandrashekar et al., 1999).  Insulin-like 
growth factor I (IGF-I) was localized in Leydig and Sertoli cells, and in primary 
spermatocytes, and insulin-like growth factor I receptors (IGF-IR) were found in 
secondary spermatocytes and spermatids (Vannelli et al., 1988).  Insulin-like growth 
factor II (IGF-II) was localized to Leydig cells in the testis (Koike and Noumura, 1995).  
These results support paracrine/autocrine roles for growth factors in cell growth, 
differentiation and development of the testis for steroidogenesis and sperm production. 
 Only a limited number of studies have been performed to investigate gene 
expression in the horse testis.  The objective of this research was to further investigate 
relationships between gene expression patterns and testicular function.  This initial study 
focused on genes related to steroid and sperm production:  namely, we studied a) 
receptors for classic pituitary-derived factors such as LHR, FSHR, PRLR and GHR; b) 
steroid receptors such as AR, ER and GR; c) growth factors such as insulin-like growth 
factors I and II and IGF-IR; and d) others such as StAR and inhibin. 
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Materials and Methods 
Animals 
 Testes were surgically removed under general anesthesia from eight mature (ages 
4-17 years), light-breed stallions with normal testis size and semen quality and from five 
mature, light-breed stallions with poor semen quality.  The surgical procedure took place 
at the Texas A&M University Large Animal Clinic.  See Table 2 below for stallion 
identification information and semen quality descriptions. 
 
 
 
 
Table 2.  Stallion identification (ID) numbers, classification group and animal 
problem/diagnosis information for horse samples used in this study. 
 
Horse ID Classification Group Animal Problem/Diagnosis 
1859 Normal  
1861 Normal  
1906 Normal  
1955 Normal  
1957 Normal  
1959 Normal  
7-5 Normal  
Arab Normal  
Peppy Poor semen quality Poor semen quality 
Leo Castelli Poor semen quality Small left testis size 
King’s Travelin Dude Poor semen quality No sperm in ejaculate 
State Dancer Poor semen quality Poor semen quality 
Millenium Impulse Poor semen quality Unilateral cryptorchid 
 
 
 
 
Normal and poor semen quality classification groups were sorted by daily sperm output 
(DSO).  Slices of testicular parenchyma were harvested from the center of the testis 
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adjacent to the central vein.  Several parenchymal samples were snap frozen in liquid 
nitrogen for RNA analysis and other samples were fixed in 4% paraformaldehyde for in 
situ hybridization. 
In Situ Hybridization (ISH) 
Testis parenchyma samples were placed in 4% paraformaldehyde overnight.  
After fixation, the samples were processed and embedded in paraffin for cutting sections.  
In situ hybridization (Wilcox, 1993) was used to determine the localization of mRNAs 
that code for GR alpha, GR beta, GR exon 2, LHR, AR and StAR in the testes (see 
Appendix C for protocol).  Briefly, slides of testis sections were deparaffinized by 
ethanol washes.  Slides were washed with SSC and treated with Proteinase K.  Sections 
were then exposed to radioactively labeled mRNA probes overnight at 55°C for 
hybridization.  After washing slides with SSC and treatment with Rnase A the slides were 
dehydrated with ethanol and allowed to dry at 37°C.  Slides were exposed to X-ray film 
at room temperature to determine optimal length of exposure to emulsion for each probe.  
Slides were dipped in emulsion that was diluted 1:1 with water at 42°C and placed at 4°C 
for 8-10 weeks.  Slides were then developed using Kodak D19 developer diluted 1:1 with 
water (15°C) and Kodak fixer.  Toludine blue was used as counter stain of cell nuclei for 
identification.  Slides were cleaned, washed with ethanol and xylene and then cover 
slipped with Permount (Fisher Scientific).  Slides were allowed to dry at least 24 hours 
before visualization under a microscope.  Localization of mRNAs in different cell types 
of the testis were identified using microscopy for grain visualization and images captured 
for validation.  NIH Image software (National Institutes of Health, Bethesda, MD) was 
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used for semi-quantitative analysis of in situ hybridization to determine the amount of 
mRNA localization in testis sections. 
RNA Isolation 
At castration, a portion of testicular parenchyma was snap frozen for RNA 
isolation and analysis.  Tripure reagent (Roche, Switzerland) was used to extract mRNA 
(see Appendix D for protocol) from various stallion tissues such as the adrenal, pituitary, 
thyroid, liver, spleen and testis.  Specifically, 0.3g of tissue was placed in 3 mL of 
Tripure reagent in a 50 mL tube.  Each sample was homogenized twice for 30 seconds 
each.  Total cellular RNA was separated from DNA and protein by first mixing the 
samples with chloroform and then centrifuging the homogenate.  The upper aqueous 
layer of RNA was then transferred to a clean tube and precipitated first with isopropanol 
and then with 70% ethanol.  RNA pellets were resuspended with diethyl pyrocarbonate-
treated (DEPC) water and heated at 68°C for 10 minutes.  Samples were then aliquoted to 
use for gel electrophoresis procedures to check mRNA integrity.  Spectrophotometry 
analysis was used to determine concentration of RNA in the samples.  Extracted mRNA 
was kept frozen at –80°C to minimize degradation. 
Integrity of extracted mRNA was confirmed using gel electrophoresis to separate 
18S and 28S ribosomal RNA bands (Figure 15).  If a sample contained degraded RNA, 
the sample would appear as a vertical smear for that sample.  All of the extracted mRNA 
samples had acceptable concentrations and RNA integrity.  Therefore, the samples were 
valid specimens for further experimentation and analysis. 
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Figure 15.  Representative 1% agarose gel image stained with ethidium bromide 
(EtBr) to allow visualization of 18S and 28S ribosomal RNA bands.  If a sample 
contained degraded RNA, the sample would appear as a vertical smear for that sample.  
This image is an example of non-degraded samples of RNA for stallion testis 
parenchyma. 
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Probe Validation 
Specificity of newly created probes for GR and LHR were verified using the 
ribonuclease protection assay procedure (RPA; see Appendix E for protocol).  
Radioactively labeled GR and LHR probes were synthesized using the Ambion 
MAXIscript in vitro transcription kit (Ambion, Inc., Austin, Texas) where one microgram 
of cDNA template was transcribed using T7 Polymerase to incorporate 32P-labeled UTP 
into the sequence.  An RPA was used to visualize and quantitate extracted RNA 
(described above) of genes of interest following Ambion’s RPA III kit (Ambion, Inc., 
Austin, Texas).  Co-precipitation of sample RNA and labeled probe was performed at –
20°C for 15 minutes.  The RNAs were pelleted by centrifugation and allowed to dry.  
Pellets were resuspended in 10 µl Hybridization Buffer, incubated at 90°C for 3 minutes 
and transferred to 42°C overnight.  Unprotected single-stranded RNA was digested and 
protected RNA was precipitated at –20°C.  Pellets were resuspended in gel loading buffer 
and loaded on a 5% denaturing polyacrylamide gel for 2 hours.  The gel was exposed to 
autoradiography film for 24-48 hours for visualization of protected RNA bands. 
Slot Blot mRNA Analysis 
Total cellular RNA was isolated using the previously described method for testis 
samples from the eight normal and five poor semen quality stallions.  The quantity of 
mRNA in the testis of each stallion was measured on replicate blots using slot blot 
northern blot techniques (See protocol Appendix J) for 18S ribosomal RNA, follicle 
stimulating hormone receptor (FHSR), LHR, StAR, GR beta, GR alpha, GR exon 2, 
prolactin receptor (PRLR), androgen receptor (AR), estrogen receptor alpha (ER alpha), 
estrogen receptor beta (ER beta), inhibin, insulin-like growth factor I (IGF-I), insulin-like 
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growth factor II (IGF-II), growth hormone receptor (GHR) and insulin-like growth factor 
I receptor (IGF-IR).  Briefly, 20 µg of mRNA was hybridized to a nylon transfer 
membrane using a Bio-Rad slot blot apparatus.  The mRNA sample was mixed with 20X 
SSC, formamide and formaldehyde then applied to the membrane using gentle vacuum 
suction.  The membrane was then washed with 10X SSC and allowed to air dry before 
baking at 80˚C for 2 hours.  The membranes were then stored at –20˚C until further use.  
Next, the membranes were placed in glass roller tubes with the hybridization buffer at 
55˚C for 1 hour in a rolling hybridization oven.  cRNA probes were synthesized using 32P 
labeled UTP.  Unincorporated nucleotides were removed by column purification and 
counts of radioactivity obtained using a Beckman scintillation counter.  One million cpm 
per mL of cRNA probe was added to each membrane using 18S ribosomal RNA as a 
control on another replicate membrane.  Probes were allowed to hybridize overnight at 
55˚C.  The next day the radioactive waste was poured in an appropriately labeled liquid 
waste container and the membranes were washed with a series of SSC/SDS washes at 
various temperatures to reduce non-specific binding of the probes to the membranes.  
Membranes were wrapped in Saran™ wrap and exposed overnight using the Typhoon 
8600 scanner and variable mode imager.  Numerical results were obtained using 
ImageQuant analysis software.  The PROC GLM and least squares means analysis of 
SAS were used to analyze density of mRNA pixels with 18S ribosomal RNA density as a 
covariate for each sample. 
Results 
 Radioactively labeled 35S probes were hybridized to slides containing stallion 
testis cross-sections.  Upon microscopic examination of the slides, the ISH silver grains 
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only faintly appeared for GR alpha, GR beta and LHR thus signal strength appears the 
same as background.  The ISH procedures need to be repeated for these genes and slides 
exposed for longer than ten weeks in order to be able to visualize silver grains and 
determine localization of mRNAs.  The low signal intensity of GR and LHR is expected 
since the expression of these steroid receptors is low in the testis.  A difference in signal 
above background is subjectively detectable with GR exon 2 and AR by microscopic 
visualization (Figures 16 and 17).  GR exon 2 mRNA localized in a general pattern over 
the interstitial space and within the seminiferous tubule to cell types throughout the testis.  
AR mRNA localized primarily to the interstitial space and the perimeter of the 
seminiferous tubules, but was not present in the center of the seminiferous tubules.  This 
would confirm the presence of AR in Leydig and Sertoli cells but not present in 
spermatozoa. 
StAR protein mRNA localized to Leydig cells in the interstitial space between 
seminiferous tubules (Figure 18).  The quantity of StAR protein mRNA localization was 
not different between normal and poor semen quality stallion testis cross-sections (36.58 
± 4.91 number of silver grains for normal and 26.84 ± 8.02 number of silver grains for 
poor semen quality; Figure 19). 
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Brightfield Image Darkfield Image 
  
1959 sense 1959 sense 
  
1959 GR exon 2 anti-sense 1959 GR exon 2 anti-sense 
 
Figure 16.  In situ localization results for the glucocorticoid receptor exon 2 (GR 
exon 2) in the stallion testis.  GR exon 2 mRNA localized in a general pattern over the 
interstitial space and within the seminiferous tubule to cell types throughout the testis.   
35S-labeled anti-sense and sense probes were hybridized to testis cross-sections in a 
normal stallion (animal number 1959).  Brightfield and darkfield images are displayed. 
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Brightfield Image Darkfield Image 
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1959 AR anti-sense 1959 AR anti-sense 
 
Figure 17.  In situ localization results for the androgen receptor (AR) in the 
stallion testis.  AR mRNA localized primarily to the interstitial space and the perimeter of 
the seminiferous tubules, but was not present in the center of the seminiferous tubules.  
This would confirm the presence of AR in Leydig and Sertoli cells but not present in 
spermatozoa.  35S-labeled anti-sense and sense probes were hybridized to testis cross-
sections in a normal stallion (animal number 1959).  Brightfield and darkfield images are 
displayed. 
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Brightfield Image Darkfield Image 
  
1959 sense 1959 sense 
  
1959 StAR anti-sense 1959 StAR anti-sense 
 
Figure 18.  In situ localization results for steroidogenic acute regulatory (StAR) 
protein in the stallion testis.  35S-labeled anti-sense and sense probes were hybridized to 
testis cross-sections in a normal stallion (animal number 1959).  Brightfield and darkfield 
images are displayed. 
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Figure 19.  Quantity of steroidogenic acute regulatory (StAR) protein mRNA (number of silver grains) in Leydig cells of testis 
cross-sections of normal and poor semen quality stallions.  Means do not differ between classification groups (P>0.05). 
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Synthesized probes for GR alpha, GR beta, GR exon 2 and LHR were hybridized 
to adrenal, pituitary, thyroid, liver, spleen and testis mRNAs.  GR alpha, GR beta and GR 
exon 2 probes hybridized to mRNA in adrenal, pituitary, thyroid, liver, spleen and testis 
tissue as expected.  The LHR probe only hybridized to testis mRNA as expected. 
 The quantity of specific mRNAs in the testis sample of each stallion was 
measured using slot blot hybridization techniques (Figure 20).  The quantity of FSHR, 
LHR, StAR, GR alpha, GR exon 2, AR, IGF-I and IGF-II mRNAs (Figures 21 to 28) did 
not differ between normal and poor semen quality stallions.  The quantity of ER alpha 
and GR beta mRNAs (Figures 29 and 30) had a tendency to be different (P<0.10) 
between normal and poor semen quality stallions.  The quantity of ER beta, βB inhibin, 
PRLR, GHR and IGF-IR mRNAs (Figures 31 to 35) were significantly different (P<0.05) 
between normal and poor semen quality stallions.  Numerical results of slot blot mRNA 
data are reported in Table 3.  
Discussion 
To date, the StAR protein has been detected in Leydig cells in the human, mouse, 
rat, bull and pig (Pollack et al., 1997; Aspden et al., 1998; Thompson et al., 1999; 
Garmey et al., 2000; Kotula et al., 2001).  Similarly, in this study StAR protein mRNA 
localized to Leydig cells in the interstitial space of the stallion testis.  There appears to be 
no difference in the amount of StAR protein mRNA present in the testis of normal and 
poor semen quality stallions used in this study.  The presence of StAR protein mRNA in 
the Leydig cells is important for cholesterol transport from the outer mitochondrial 
membrane to the inner mitochondrial membrane for steroid biosynthesis (Pollack et al., 
1997).   
 
 54
 
 
 1               2              3                4              5               6
A 
B 
C 
 
 
 
Figure 20.  Representative slot blot of IGF-II mRNA in tissue from stallion testis 
samples.  Wells A1 through A6 represent one row containing six different RNA samples.  
The slot blot apparatus is able to hold 48 different RNA samples at one time for RNA 
analysis.  Stallion testis sample locations are as follows:  A1=1859, A2=Lucky left testis, 
A3=1906, A4=1861, A5=Peppy, A6=1959, B1= 1957, B2=Peanut Butter left testis, 
B3=Lucky right testis, B4=7-5, B5=King’s Travelin Dude, B6=1955, C1=Arab, C2=Leo 
Castelli, C3=Peanut Butter right testis, C4=Millenium Impulse, C5=State Dancer right 
testis and C6=State Dancer left testis.  Samples were taken from the left testis unless 
stated otherwise.  Not all of the stallions listed above were used in this study.  The slot 
blot image was obtained using the Typhoon 8600 scanner variable mode imager. 
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Figure 21.  Quantity of follicle-stimulating hormone receptor (FSHR) mRNA (density of pixels) in the testis of normal and 
poor semen quality stallions.  Means do not differ between classification  groups (P>0.05). 
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Figure 22.  Quantity of luteinizing hormone receptor (LHR) mRNA (density of pixels) in the testis of normal and poor semen 
quality stallions.  Means do not differ between classification groups (P>0.05). 
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Figure 23.  Quantity of steroidogenic acute regulatory (StAR) protein mRNA (density of pixels) in the testis of normal and 
poor semen quality stallions.  Means do not differ between classification groups (P>0.05). 
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Figure 24.  Quantity of glucocorticoid receptor alpha (GR alpha) mRNA (density of pixels) in the testis of normal and poor 
semen quality stallions.  Means do not differ between classification groups (P>0.05). 
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Figure 25.  Quantity of glucocorticoid receptor exon 2 (GR exon 2) mRNA (density of pixels) in the testis of normal and poor 
semen quality stallions.  Means do not differ between classification groups (P>0.05). 
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Figure 26.  Quantity of androgen receptor (AR) mRNA (density of pixels) in the testis of normal and poor semen quality 
stallions.  Means do not differ between classification groups (P>0.05). 
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Figure 27.  Quantity of insulin-like growth factor I (IGF-I) mRNA (density of pixels) in the testis of normal and poor semen 
quality stallions.  Means do not differ between classification groups (P>0.05). 
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Figure 28.  Quantity of insulin-like growth factor II (IGF-II) mRNA (density of pixels) in the testis of normal and poor semen 
quality stallions.  Means do not differ between classification groups (P>0.05). 
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Figure 29.  Quantity of estrogen receptor alpha (ER alpha) mRNA (density of pixels) in the testis of normal and poor semen 
quality stallions.  Means with different subscripts differ (P<0.10). 
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Figure 30.  Quantity of glucocorticoid receptor beta (GR beta) mRNA (density of pixels) in the testis of normal and poor 
semen quality stallions.  Means with different subscripts differ (P<0.10). 
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Figure 31.  Quantity of estrogen receptor beta (ER beta) mRNA (density of pixels) in the testis of normal and poor semen 
quality stallions.  Means with different subscripts differ (P<0.05). 
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Figure 32.  Quantity of βB inhibin mRNA (density of pixels) in the testis of normal and poor semen quality stallions.  Means 
with different subscripts differ (P<0.05). 
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Figure 33.  Quantity of prolactin receptor (PRLR) mRNA (density of pixels) in the testis of normal and poor semen quality 
stallions.  Means with different subscripts differ (P<0.05). 
 
 67
 
 0.00E+00
5.00E+05
1.00E+06
1.50E+06
2.00E+06
2.50E+06
3.00E+06
Classification Group
G
H
R
 
m
R
N
A
,
 
d
e
n
s
i
t
y
 
o
f
 
p
i
x
e
l
s
Normal
Poor semen quality
n=8 n=5
a
b
 
Figure 34.  Quantity of growth hormone receptor (GHR) mRNA (density of pixels) in the testis of normal and poor semen 
quality stallions.  Means with different subscripts differ (P<0.05). 
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Figure 35.  Quantity of insulin-like growth factor I receptor (IGF-IR) mRNA (density of pixels) in the testis of normal and 
poor semen quality stallions.  Means with different subscripts differ (P<0.05). 
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Table 3.  Summation of slot blot mRNA results (density of pixels) for FSHR, LHR, 
StAR, GR alpha, GR exon 2, AR, IGF-I, IGF-II, ER alpha, GR beta, ER beta, βB inhibin, 
PRLR, GHR and IGF-IR mRNAs in normal and poor semen quality stallion testis RNA.  
Comparison is between normal and poor semen quality stallion testis samples within gene 
and not between gene. 
 
mRNA Normal 
Stallion 
Mean 
(density of 
pixels) 
Normal 
Stallion 
Standard 
Deviation 
(density of 
pixels) 
Poor Semen 
Quality 
Stallion 
Mean 
(density of 
pixels) 
Poor Semen 
Quality 
Stallion 
Standard 
Deviation 
(density of 
pixels) 
P-value 
FSHR 2.70x10e6 1.15x10e5 2.62x10e6 1.55x10e5 0.72 
LHR 2.52x10e6 1.49x10e5 2.38x10e6 2.01x10e5 0.64 
StAR 2.78x10e7 2.09x10e6 2.99x10e7 2.82x10e6 0.61 
GR alpha 1.09x10e6 3.12x10e4 1.12x10e6 4.21x10e4 0.69 
GR exon 2 4.29x10e6 1.48x10e5 4.15x10e6 2.00x10e5 0.63 
AR 3.75x10e6 7.88x10e4 3.77x10e6 1.06x10e5 0.91 
IGF-I 2.00x10e6 6.87x10e4 2.00x10e6 9.27x10e4 0.99 
IGF-II 3.56x10e7 1.40x10e6 3.71x10e7 1.90x10e6 0.58 
ER alpha 2.71x10e6 6.54x10e4 2.93x10e6 8.83x10e4 0.09 
GR beta 8.64x10e5 1.99x10e4 7.89x10e5 2.69x10e4 0.07 
ER beta 1.84x10e7 7.53x10e5 1.39x10e7 1.02x10e6 0.01 
βB inhibin 2.61x10e7 9.86x10e5 2.18x10e7 1.33x10e6 0.04 
PRLR 6.73x10e7 1.57x10e6 5.80x10e7 2.12x10e6 0.01 
GHR 2.24x10e6 8.11x10e4 1.72x10e6 1.09x10e5 0.01 
IGF-IR 7.14x10e5 2.27x10e4 5.87x10e5 3.06x10e4 0.01 
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GR is another important endocrine gene in the stallion.  In this study, GR exon 2 
mRNA localized in a general pattern over the interstitial space and within the 
seminiferous tubule to cell types throughout the testes.  Previously, GR was identified in 
Leydig cells, Sertoli cells and germ cells in the testes of the human and rat (Weber et al., 
2000).  AR mRNA localized primarily to the interstitial space and the perimeter of the 
seminiferous tubules, but was not present in the center of the seminiferous tubules.  This 
would confirm the presence of AR in Leydig and Sertoli cells but not present in 
spermatozoa.  Previously, the presence of AR was reported in Leydig and Sertoli cells in 
the human, mouse, rat and pig testes (Namiki et al., 1991; Ruizeveld de Winter et al., 
1991; Kotula et al., 2000; Pelletier et al., 2000; Zhou et al., 2002). 
In the future, the slot blot northern blot technique should be tested further to 
determine the optimal amount of RNA that binds the nylon membrane.  This will 
determine if the 18S ribosomal RNA control binds in excess on the membrane, which is 
necessary for accurate results.  This is a potential problem with the data reported in this 
study and results would need to be confirmed with lower amounts of RNA bound to the 
membrane if the 18S ribosomal RNA control is not in excess with 20 µg of RNA per slot. 
LHR mRNA is present in stallion testes, but not in adrenal gland, pituitary gland, 
thyroid liver or spleen and has been shown in other species.  This confirms the specificity 
of the newly designed LHR probe.  GR alpha, GR beta and GR exon 2 mRNAs are 
present in various stallion tissues besides the testes, including the adrenal gland, pituitary 
gland, thyroid, liver and spleen.  These results are the same as observed by other 
investigators in the human and rat (Weber et al., 2000; Pujols et al., 2002).  Both 
isoforms GR alpha and beta were present in stallion testes.  Previously this information 
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was unknown since the synteny of GR beta is not conserved across species and is absent 
in the mouse (Otto et al., 1997).  GR beta is hypothesized to be involved in blocking 
ligand binding to GR alpha, thereby causing glucocorticoid resistance in the animal.  
Because of this, the use of long-term glucocorticoid treatment in the horse should be 
reconsidered to avoid problems with glucocorticoid resistance.  Further studies are 
necessary to determine the physiological significance of GR beta in the stallion testis and 
the effects of glucocorticoids on reproduction. 
The quantity of FSHR and LHR mRNAs were not different in testes of normal 
and poor semen quality stallions, indicating there is not a correlation between 
gonadotroph secretion or gonadotroph receptor binding and semen quality.  These 
stallions of poor semen quality were not different in FSH concentration than stallions 
with normal semen quality.  There was no difference in the quantity of StAR protein or 
AR mRNA in the testis between normal and poor semen quality stallions.  Therefore, 
StAR protein transport of cholesterol to the inner mitochondrial membrane for steroid 
production and the use of androgens by binding the AR in the Leydig and Sertoli cells 
was not the cause of poor semen quality.  Also, the quantity of GR alpha, GR exon 2, 
IGF-I and IGF-II mRNAs was not different between normal and poor semen quality 
stallions.  This would indicate that glucocorticoid action in the testis was not the cause of 
poor semen quality.  But, if the GR is present, it could be dependent on ligand and its 
availability for ligand to be different in poor semen quality.  Also, the IGF-I and IGF-II 
growth factors are not responsible for poor semen quality in the stallion. 
The quantity of ER alpha mRNA had a tendency (P<0.10) to be higher in the 
testes of poor semen quality stallions.  This could indicate that estrogen production in the 
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testis is important in paracrine/autocrine regulation of spermatogenesis and normal 
testicular function.  The role of estrogen and estrogen receptors in the testis remains 
unclear.  Further investigations with a larger number of normal and poor semen quality 
stallions are needed in order to determine if there is indeed an effect of estrogen on semen 
quality.  GR beta mRNA quantity had a tendency to be lower in the testes of poor semen 
quality stallions.  The functional role of GR beta is still unknown.  The lack of GR beta in 
the mouse raises questions about physiological significance of the gene isoform since the 
GR alpha isoform is known to be the biologically active form in humans and rats (Otto et 
al., 1997; Pujols et al., 2002).  Further studies are needed to determine the importance and 
necessity of GR beta in the stallion testes and its functional role in spermatogenesis and 
steroidogenesis. 
There were several mRNAs expressed in differing quantities in normal and poor 
semen quality stallions.  ER beta mRNA was significantly lower in poor semen quality 
stallions than in normal stallions.  While ER alpha knockout mice are completely 
infertile, ER beta knockout mice appear to have no compromised fertility (Couse et al., 
2001).  This would indicate that the presence of ER alpha in the stallion testis is required 
for fertility but the varying importance of the two isoforms remains unknown.  Further 
studies are necessary in order to elucidate the different roles of ER alpha and ER beta in 
the stallion testis.  The quantity of βB inhibin mRNA was lower in the poor semen 
quality stallion than in the normal stallion testes.  Since inhibin is an important regulator 
of gonadotroph secretion and is important in paracrine regulation of testicular function 
(Marchetti et al., 2003), changes in inhibin secretion could be an indicator of fertility 
status (von Eckardstein et al., 1999; Hu et al., 2003).  There appears to be an association 
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between circulating inhibin concentration and level of stallion fertility (Stewart and 
Roser, 1998) such that fertile stallions have higher circulating concentrations of inhibin 
and higher mRNA expression of inhibin in the testis.  Further investigation is needed in 
order to understand the changes in mRNA expression in poor semen quality stallions. 
Differences in mRNA expression were observed for several 
somatogenic/lactogenic gene receptors in the poor semen quality stallions.  The quantity 
of PRLR, GHR and IGF-IR mRNAs were all lower in poor semen quality stallions than 
in normal stallions.  Hormones such as prolactin, growth hormone and IGF-I appear to 
play an important autocrine/paracrine role in the testis (Spiteri-Grech and Nieschlag, 
1993; Gnessi et al., 1997; Schlatt et al., 1997).  IGF-I has been shown to stimulate 
proliferation of Sertoli cells and spermatogonia through IGF-IR (Jaillard et al., 1987; 
Soder et al., 1992).  Poor semen quality stallions had a reduced GHR mRNA expression.  
Similarly, GHR knockout mice were shown to have reduced fertility (Chandrashekar et 
al., 1999).  Further investigation is needed in the stallion to determine the affects of 
PRLR, GHR and IGF-IR expression on fertility. 
This research supplies information about gene expression in the stallion testis as 
well as preliminary information useful in the study of semen quality.  Future studies are 
needed in order to understand the causes of poor semen quality in the stallion. 
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CHAPTER V 
SEMEN EVALUATION AND IN VITRO TESTIS CULTURE IN NORMAL 
AND POOR SEMEN QUALITY STALLIONS 
Introduction 
 Spermatogenesis and steroidogenesis are important functions of the testis and are 
necessary for fertility of an animal.  Spermatogenesis is a developmental process that 
results in the production of sperm in the male while steroidogenesis is the pathway by 
which steroid hormones are produced from cholesterol (Senger, 1999).  Breeding 
soundness exams (BSE) are used to examine the reproductive organs, the behavior, the 
quantity and quality of ejaculate and the function of the reproductive endocrine system 
(Juhasz et al., 2000).  Due to the high individual value of stallions and the relative 
incidence of fertility disorders, there is interest in detection methods for fertility 
parameters (Juhasz et al., 2000).  Daily sperm production (DSP) and DSP per gram of 
parenchyma referred to as spermatogenic efficiency are two parameters used to quantitate 
sperm production (Senger, 1999).  Hormone measurements are also used to evaluate the 
function of the reproductive system of an animal.  Measuring baseline concentrations of 
reproductive hormones occasionally identifies hormonal imbalances that could be 
associated with subfertility (Juhasz et al., 2000). 
 Normal spermatogenesis is a relatively inefficient process that results in the loss 
of a large number of potential spermatozoa (Clermont, 1962; Huckins, 1978).  Apoptosis 
or programmed cell death has been implicated in the testis as an essential mechanism for 
removal of developing germ cells from the seminiferous epithelium (Knudson et al., 
1995; Rodriguez et al., 1997; Russell et al., 2002) and has recently been demonstrated in 
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the testis of normal stallions (Heninger et al., 2004).  Since basal levels of germ cell 
apoptosis have been identified for normal stallions, further research evaluating the role of 
apoptosis in the poor semen quality stallion is possible and would add useful information 
for the understanding of molecular mechanisms in the testis. 
 Normal spermatogenesis is dependent upon a functional hypothalamic-pituitary-
testicular (HPT) axis, which involves classic endocrine actions of gonadotropins, 
feedback mechanisms of steroids and proteins and paracrine/autocrine modulation 
(Roser, 2001).  This includes such hormones as LH, FSH, testosterone, estradiol, inhibin 
and IGF-I as well as many others.  LH, through the production of testosterone, and FSH 
hormones are required by the testis for maintenance of spermatogenesis (De Kretser et 
al., 1995).  Also, testicular estrogen appears to regulate reproductive function in the 
stallion (Thompson and Honey, 1984; Muyan et al., 1993).  Numerous studies have 
demonstrated that testosterone and estradiol inhibit LH secretion and inhibin inhibits FSH 
secretion (De Kretser et al., 1995).  Since all of these hormones create homeostasis in the 
testis for spermatogenesis, information could be gained by demonstrating hormonal 
changes that relate to poor semen quality.  In stallions, a positive correlation exists 
between plasma immunoreactive (ir)-inhibin and testicular activity (Nagata et al., 1998a).  
Motton and Roser (1997) indicate that plasma LH, FSH, estradiol and testosterone 
concentrations are not different between normal and poor semen quality stallions, but that 
LH and FSH were significantly higher and estradiol, testosterone and inhibin 
concentrations were significantly lower in infertile stallions.  Also, Hess and Roser 
(2001) state that plasma IGF-I concentration does not have a direct relationship with 
declining fertility in stallions. 
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 In vitro culture methods are useful to test specific questions about tissue function 
in a more controlled environment.  Culturing testicular parenchyma allows for addition of 
compounds such as hCG, which elicits an LH-like response without affecting FSH 
activity, and forskolin.  HCG stimulation tests the LHR signaling mechanisms in the 
stallion testis, while forskolin stimulates the second messenger system through activation 
of adenylate cyclase bypassing the LH receptor.  Both hCG and forskolin activate 
steroidogenesis in Leydig cells to stimulate synthesis of testosterone.  Testosterone assays 
are then used to detect changes due to in vitro challenges of the testis.  This is a 
diagnostic tool to directly test the secretory capacity of the Leydig cells (Juhasz et al., 
2000). 
 Other changes such as gene expression in the testis can be measured to determine 
relationships of hormone pathways and second messenger systems.  The biosynthesis of 
all steroid hormones begins with the transport of cholesterol from the outer mitochondria 
to the inner mitochondrial membrane by StAR protein (Stocco and Clark, 1996).  
Subsequently, the conversion of cholesterol to pregnenolone by the cytochrome P450scc 
enzyme complex takes place and starts the cascade of enzymatic reactions for 
testosterone production (Kerban et al., 1999).  Previous studies have demonstrated 
regulation of StAR mRNA with hCG treatment (Kerban et al., 1999) which suggests that 
hCG challenges affect gene expression in the testis.  Changes in StAR and P450scc 
proteins can be measured using western blot techniques to analyze differences in 
expression due to hCG or forskolin treatment in the testis. 
 By using methods such as seminal parameter measurements, apoptotic rate, 
hormone concentrations and in vitro culture techniques testicular function of an animal 
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can be evaluated.  Further research is needed in order to define the normal limits of these 
parameters for stallions so that poor semen quality or infertile animals can be assessed 
and treated. 
Materials and Methods 
Animals 
 Testes were surgically removed under general anesthesia from eight mature (ages 
4-17 years), light-breed stallions with normal testes size and semen quality and from five 
mature, light-breed stallions with poor semen quality.  See Table 2 (page 42) for stallion 
identification information and semen quality descriptions.  Normal and poor semen 
quality classification groups were sorted by daily sperm output.  Slices of testicular 
parenchyma were harvested from the center of the testis adjacent to the central vein.  
Parenchymal samples were 1) snap frozen in liquid nitrogen for RNA and protein 
evaluation, 2) fixed in 4% paraformaldehyde for detection of apoptosis and 3) placed on 
ice for in vitro culture use. 
Semen Quality Evaluation 
Daily Sperm Production (DSP).  Estimation of DSP was performed according to 
previously established methods (Amann, 1962).  Briefly, 0.2 to 0.5 grams of 2% 
glutaraldehyde fixed testicular parenchyma were homogenized in a Waring blender for 6 
minutes in 100 ml of fluid containing 150 mM NaCl, 0.05% (v/v) Triton X-100 and 3.8 
mM NaN3.  Maturation-phase elongated spermatids were enumerated using duplicate 
evaluations for a single observer.  DSP per gram parenchyma (DSP/g) was calculated for 
each horse as the number of elongated homogenization-resistant spermatids divided by 
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the product of the weight of the homogenized tissue and the lifespan of the spermatids 
(8.2 days). 
Seminal Parameters.  Daily Sperm Output (DSO) was estimated by evaluation 
of sperm numbers in ejaculates after extragonadal sperm reserves were stabilized (Varner 
et al., 1991).  Sperm concentrations in an ejaculate were determined using a densimeter 
(Animal Reproduction Systems, Chino, CA).  Semen samples were also evaluated for 
motility (% total motile sperm), progressive motility (% progressively motile sperm, 
PMS) and morphology (% morphologically normal sperm, MNS). 
Apoptosis.  Apoptosis was measured using fixed parenchymal samples as 
described in Heninger et al., 2004 for TUNEL immunohistochemistry.  Briefly, to 
quantify germ cell apoptotic rates in reproductively normal and poor semen quality 
stallions, an ApopTag® peroxidase detection kit S7100 (TUNEL) (Intergenco, Purchase, 
NY, USA) was used according to manufacturer’s instructions.  Apoptosis quantification 
was performed by counting the number of TUNEL-positive germ cells per one hundred 
Sertoli cells to obtain a value of apoptosis for each animal. 
Hormone Assays 
 Blood samples were collected via jugular venipuncture.  Plasma samples were 
isolated by centrifugation for 10 minutes at 10,000xg.  The blood samples were frozen at 
–20ºC.  Samples were analyzed for testosterone, estradiol, luteinizing hormone (LH), 
follicle stimulating hormone (FSH) and inhibin by radioimmunoassay (RIA) (Courtesy of 
J. F. Roser, Department of Animal Science, University of California, Davis, CA).  LH, 
FSH and testosterone RIAs were performed according to Roser and Hughes (1991).  The 
estradiol RIA was performed following procedures from Pinaud et al. (1991) and 
 
 80
immunoreactive inhibin was assayed according to Roser et al. (1994).  All blood samples 
were measured in one assay for each hormone to avoid assay variation. 
IGF-I Concentration 
The concentration of IGF-I was also measured in the blood samples of normal and 
poor semen quality stallions by RIA (see Appendix I for protocol) as described by Bilby 
et al, 1999 with a few modifications.  All blood samples were measured in one assay to 
avoid assay variation.  Briefly, 10 µl of serum was pipetted into polypropylene 12X75 
tubes and extracted with 400 µl 1M glycine (pH 3.2) and 500 µl IGF-I assay buffer (pH 
3.5) at 37ºC for 48 hours.  Next, 90 µl of 0.5N NaOH was added to each extracted sample 
and vortexed to neutralize the pH to 7.0.  The assay standards and acidified unknowns 
were then pipetted in duplicate into polypropylene 12X75 tubes using 50 µl of extracted 
sample volume.  100 µl of rabbit anti-human IGF-I (UB3-189; A. F. Parlow, National 
Hormone and Peptide Program, Torrance, CA) antibody (1:120,000 dilution) was added 
to assay tubes, mixed and incubated at 4ºC for 24 hours.  100 µl of 125I-IGF-I tracer (cat# 
68128; MP Biomedicals (formerly ICN), Irvine, CA) was added to all assay tubes, mixed 
and incubated for 16 hours at 4ºC.  Next, 50 µl of normal rabbit serum (NRS), 50 µl of 
goat anti-rabbit IgG (GARGG; 1:60 dilution) secondary antibody (Calbiochem, San 
Diego, CA) and 300 µl of polyethylene glycol were added to assay tubes, mixed and 
incubated at room temperature for 30 minutes.  Assay tubes were centrifuged at 3000 rcf 
for 30 minutes at 4ºC and supernatant decanted into a radioactive waste container.  Assay 
tubes were counted with a Beckman gamma counter for 1 minute.  Unknown samples 
were analyzed using AssayZap (Biosoft Inc., Cambridge, UK) to calculate concentrations 
of unknowns in comparison to a known standard curve.  
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In Vitro Culture 
Parenchymal samples were collected from testes of normal and poor semen 
quality stallions.  Fresh tissue was kept on ice and transported to the laboratory for in 
vitro culture (see Appendix F for protocol).  One gram of testicular parenchyma was 
weighed and incubated in 5 mL of DMEM (cat# 1600034; Gibco Invitrogen Corp., 
Carlsbad, CA) media containing Penicillin/Streptomycin (cat# 5070063; Gibco 
Invitrogen Corp., Carlsbad, CA) in a 50 mL tube.  Samples were incubated at 34°C with 
95% O2/5% CO2 exposure in a shaking water bath.  After two hours of incubation, media 
was removed and frozen.  Treatments either of media alone, 10 international units per ml 
(IU/ml) human chorionic gonadotropin (hCG; Pregnyl from Organon, West Orange, NJ), 
100 IU/ml hCG or 10-5 M forskolin (cat# 80058-086; VWR, West Chester, PA) were 
added to the testis samples and incubated for another two hours.  After two hours, the 
samples were divided into either 2-hr or 4-hr treatment groups.  Media from the 2-hr 
treatment group was collected and frozen at –20°C.  The testis samples were frozen in an 
Rnase-free tube at –80°C.  The 4-hr incubation samples had 200 µl of media removed and 
frozen.  The remainder of the media continued to incubate for another two hours.  After 
4-hr of incubation, the 4-hr sample media and testis tissue were collected and frozen as 
described above. 
Testosterone Concentrations 
Testosterone concentrations were measured using radioimmunoassay (RIA; see 
Appendix H for protocol) for circulating testosterone production as well as testosterone 
produced in vitro from cultured testicular cells (mentioned above) (Godfrey et al., 1990; 
French and Welsh, 1990).  All blood samples were measured in one assay to avoid assay 
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variation.  Blood serum or media from culture was pipetted into 12X75 polypropylene 
tubes and brought to 500 µl volume with PBSG diluent.  100 µl of testosterone antibody 
(Colorado State University) and 100 µl of 3H-testosterone tracer (Perkin Elmer-NEN, 
Boston, MA) were added to each sample, mixed and incubated for 16-20 hours at 4°C.  
200 µl of charcoal/dextran mixture was added to each tube, vortexed and incubated at 
4°C for 20 minutes.  Samples were centrifuged at 2000xg for 30 minutes and poured into 
scintillation tubes containing 5 mL of Ecolume biodegradable scintillation cocktail (cat# 
882470; MP Biomedicals, Irvine, CA).  Samples were counted for 1 minute using a 
Beckman beta counter.  Unknown samples were analyzed using AssayZap (Biosoft Inc., 
Cambridge, UK) to calculate concentrations of unknowns in comparison to a known 
standard curve. 
Western Blot 
 StAR protein and cytochrome P450 side-chain cleavage (P450scc) enzyme 
protein expressions were measured in the same normal and poor semen quality stallions 
using western blot techniques (see Appendix G for protocol).  StAR and P450scc proteins 
were measured in freshly frozen testis tissue as well as from testicular cells cultured with 
in vitro hCG and forskolin treatments.  Proteins were extracted using Tris-Sucrose-EDTA 
homogenization fluid.  Protein samples were run on a 12.5% polyacrylamide gel and 
transferred to a nitrile membrane.  The membrane was blocked with blocking buffer, 
probed with StAR primary antibody (Dr. Stocco, Texas Tech University, TX) and anti-
rabbit IgG secondary antibody (cat# NA934; Amersham Biosciences, Piscataway, NJ).  
The membrane was developed with chemiluminescence reagents (NEN, Boston, MA) 
and exposed to X-ray film for band visualization.  The same membranes were also 
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stripped and re-probed with P450scc primary antibody (cat# AB1244; Chemicon 
International, Inc., Temecula, CA) and the same secondary antibody used previously.  
Chemiluminescence reagents were used to develop membranes for exposure to X-ray 
film (cat# RPN 1678 H, Hyperfilm MP; Amersham Pharmacia, Piscataway, NJ). 
Results 
Semen Quality Evaluation 
Left and right testicular parenchymal weight (Figure 36) and total testicular 
parenchymal weight (Figure 37) was significantly different (P<0.05) between normal and 
poor semen quality stallions.  Left and right testis daily sperm production (DSP) per gram 
of parenchyma, mean DSP per gram of parenchyma, left and right testis DSP per testis 
and DSP per horse (Figures 38-41) were significantly different (P<0.05) between normal 
and poor semen quality stallions.  Prior to castration, semen was collected to determine 
daily sperm output (DSO) and motility, progressive motility and morphology were 
evaluated.  DSO, total motility, progressively motile sperm (PMS) and morphologically 
normal sperm (MNS) (Figures 42 to 45) were significantly different (P<0.05) between 
normal and poor semen quality stallions.  Apoptosis quantification was performed by 
counting the number of TUNEL-positive germ cells per one hundred Sertoli cells for 
each stallion.  Left and right testis apoptotic rate (Figure 46) and mean apoptotic rate 
(Figure 47) were significantly different (P<0.05) between normal and poor semen quality 
stallions
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Figure 36.  Left and right testicular parenchymal weight (g) for normal and poor semen quality stallions (n = number of 
stallions per classification group).  Means with different subscripts differ (P<0.05). 
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Figure 37.  Total testicular parenchymal weight (g) for normal and poor semen quality stallions (n = number of stallions per 
classification group).  Means with different subscripts differ (P<0.05). 
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Figure 38.  Left and right daily sperm production (DSP) per gram of parenchyma for normal and poor semen quality stallions 
(n = number of stallions per classification group).  Means with different subscripts differ (P<0.05). 
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Figure 39.  Mean daily sperm production (DSP) per gram of parenchyma for normal and poor semen quality stallions (n = 
number of stallions per classification group).  Means with different subscripts differ (P<0.05). 
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Figure 40.  Left and right daily sperm production (DSP) per testis for normal and poor semen quality stallions (n = number of 
stallions per classification group).  Means with different subscripts differ (P<0.05). 
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Figure 41.  Daily sperm production (DSP) per horse for normal and poor semen quality stallions (n = number of stallions per 
classification group).  Means with different subscripts differ (P<0.05). 
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Figure 42.  Daily sperm output (10e6) per horse for normal and poor semen quality stallions (n = number of stallions per 
classification group).  Means with different subscripts differ (P<0.05). 
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Figure 43.  Total motility (%) per horse for normal and poor semen quality stallions (n = number of stallions per classification 
group).  Means with different subscripts differ (P<0.05). 
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Figure 44.  Progressively motile sperm (%, PMS) per horse for normal and poor semen quality stallions (n = number of 
stallions per classification group).  Means with different subscripts differ (P<0.05). 
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Figure 45.  Morphologically normal sperm (%, MNS) per horse for normal and poor semen quality stallions (n = number of 
stallions per classification group).  Means with different subscripts differ (P<0.05). 
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Figure 46.  Left and right testis mean number of apoptotic germ cell nuclei per 100 Sertoli cell nuclei in normal and poor 
semen quality stallions (n = number of stallions per classification group).  Means with different subscripts differ (P<0.05). 
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Figure 47.  Mean number of apoptotic germ cell nuclei per 100 Sertoli cell nuclei in normal and poor semen quality stallions (n 
= number of stallions per classification group).  Means with different subscripts differ (P<0.05). 
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Hormone Assays 
Mean plasma testosterone and LH concentrations (Figures 48 and 49) were not 
different between normal and poor semen quality stallions.  Mean plasma estradiol and 
inhibin concentrations (Figures 50 and 51) were significantly different (P<0.05) between 
normal and poor semen quality stallions.  Mean plasma FSH concentration (Figure 52) 
had a tendency (P<0.10) to be higher in poor semen quality stallions than in normal 
stallions.  Mean serum IGF-I concentration (Figure 53) had a tendency (P<0.10) to be 
lower in poor semen quality stallions than in normal stallions.  
In Vitro Culture 
 Testosterone output with hCG treatment in vitro (Figure 54) did not differ 
between normal and poor semen quality stallions.  The testosterone response ratio with 
forskolin treatment in vitro (Figure 55) had a tendency to be lower (P<0.10) in poor 
semen quality stallions than normal stallions.  Testis content of StAR protein with hCG 
treatment in vitro (Figure 56) did not differ between normal and poor semen quality 
stallions. 
Western Blot 
Western blot analysis was used to measure testis content of StAR and P450scc 
proteins (Figures 57 and 58).  Concentrations of the StAR and P450scc proteins were not 
different between normal and poor semen quality stallions (Figures 59 and 60). 
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Figure 48.  Mean plasma testosterone concentration (ng/mL) for normal and poor semen quality stallions (n = number of 
stallions per classification group).  Means do not differ between treatment groups. 
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Figure 49.  Mean plasma luteinizing hormone (LH) concentration (pg/mL) for normal and poor semen quality stallions (n = 
number of stallions per classification group).  Means do not differ between treatment groups. 
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Figure 50.  Mean plasma estradiol concentration (pg/mL) for normal and poor semen quality stallions (n = number of stallions 
per classification group).  Means with different subscripts differ (P<0.05). 
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Figure 51.  Mean plasma ir-inhibin concentration (ng/ml) for normal and poor semen quality stallions (n = number of stallions 
per classification group).  Means with different subscripts differ (P<0.05). 
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Figure 52.  Mean plasma follicle-stimulating hormone (FSH) concentration (ng/ml) for normal and poor semen quality 
stallions (n = number of stallions per classification group).  Means with different subscripts differ (P<0.10). 
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Figure 53.  Mean serum insulin-like growth factor I (IGF-I) concentration (ng/ml) for normal and poor semen quality stallions 
(n = number of stallions per classification group).  Means with different subscripts differ (P<0.10). 
 
 102
 
 0
20
40
60
80
100
120
140
160
180
Classification Group
T
e
s
t
o
s
t
e
r
o
n
e
 
o
u
t
p
u
t
,
 
n
g
Normal
Poor semen quality
n = 8 n = 4
 
Figure 54.  Testosterone output (ng) with hCG treatment in vitro in normal and poor semen quality stallions (n = number of 
stallions per classification group).  Means do not differ between treatment groups (P>0.05). 
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Figure 55.  Testosterone response ratio with forskolin treatment in vitro in normal and poor semen quality stallions (n = 
number of stallions per classification group).  Means with different subscripts differ (P<0.10). 
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Figure 56.  Testis content of StAR protein (IOD) with hCG treatment in vitro in normal and poor semen quality stallions (n = 
number of stallions per classification group).  Means do not differ between treatment groups (P>0.05). 
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Figure 57.  Western blot analysis of steroidogenic acute regulatory (StAR) protein 
expression in the testis of normal and poor semen quality stallions.  Lane 1 contains the 
30-kDa StAR protein positive control consisting of MA10 cells cultured from the mouse 
MA10 Leydig cell line.  Lanes 2 through 5 demonstrate StAR content in four different 
poor semen quality stallions while lanes 6 through 9 demonstrate StAR content in four 
different normal stallions. 
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Figure 58.  Western blot analysis of cytochrome P450 side-chain cleavage 
enzyme (P450scc) protein expression in the testis of normal and poor semen quality 
stallions.  Lane 1 contains the 47-kDa P450scc positive control consisting of MA10 cells 
cultured from the mouse MA10 Leydig cell line.  Lanes 2 through 5 demonstrate P450scc 
content in four different poor semen quality stallions while lanes 6 through 9 demonstrate 
P450scc content in four different normal stallions. 
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Figure 59.  Testis tissue content of StAR protein (IOD) in normal and poor semen quality stallions (n = number of stallions per 
classification group).  Means do not differ between treatment groups (P>0.05). 
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Figure 60.  Testis tissue content of P450scc protein (IOD) in normal and poor semen quality stallions (n = number of stallions 
per classification group).  Means do not differ between treatment groups (P>0.05)
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Discussion 
The parameters that reflect endocrine and gametogenesis function of the testis 
consistently demonstrated statistical differences between the normal group and poor 
semen quality group of stallions.  The testicular parenchymal weights were statistically 
different between the normal and poor semen quality stallions.  Also, all DSP 
measurements were significantly different between normal and poor semen quality 
stallions.  Previously, a high correlation was reported between parenchymal weight and 
DSP (Johnson et al., 1994).  Similarly, in this study total parenchymal (PAR) weight 
(WT) was highly correlated with mean DSP per gram (DSP/g) PAR WT (r=0.7560; 
P<0.0044) and DSP per horse (DSPH) (r=0.9640; P<0.0001).  Left testis (LT) PAR WT 
was correlated with LT DSP/g (r=0.8089; P<0.0014) and LT DSP per testis (DSPT; 
r=0.95101; P<0.0001).  Right testis (RT) PAR WT was positively correlated with RT 
DSP/g (r=0.6952; P<0.0121) and RT DSPT (r=0.9402; P<0.0001).   
DSO, motility, PMS and MNS were significantly different between normal and 
poor semen quality stallions.  These parameters of spermatogenesis indicate that the 
stallions in the poor semen quality group had testicular abnormalities leading to small 
testis size and low sperm production.  The sperm that were collected in the poor semen 
quality group also had problems with motility and morphology.  DSO, motility, PMS and 
MNS were all correlated with the following:  LT PAR WT, LT DSP/g, LT DSPT, RT 
PAR WT, RT DSP/g, RT DSPT, total PAR WT, DSPH and Mean DSP/g (r=0.6195 to 
r=0.9096; P<0.0001 to P<0.0317) except PMS was not correlated with RT PAR WT.  All 
of these data indicate that the size of the testes is related to sperm production, motility 
and morphology in the stallion. 
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Left and right testis apoptotic rate and mean apoptotic rate were significantly 
different between normal and poor semen quality stallions.  LT apoptotic rate was 
inversely correlated with LT PAR WT (r=-0.6563; P<0.0283), LT DSPT (r=-0.6401; 
P<0.0339), total PAR WT (r=-0.6605; P<0.0376) and DSPH (r=-0.6788; P<0.0309).  
Similar inverse correlations were present for the RT.  Mean apoptotic rate was inversely 
correlated with all PAR WT measurements and DSP parameters.  The mean apoptotic 
rate was also inversely correlated with DSO (r=-0.7375; P<0.0040), motility (r=-0.6279; 
P<0.0216), PMS (r=-7057; P<0.0070) and MNS (r=-0.8768; P<0.0001).  This 
information suggests that the amount of cell death that takes place in the stallion testis is 
a result of the size of the testes.  Because of this, scrotal width measurements taken when 
performing BSE evaluations on stallions can be a useful tool in predicting apoptotic rate, 
DSP, DSO, motility, PMS and MNS.  In order for this to be effective, future studies need 
to be performed to determine the relationship between scrotal width and parenchymal 
weight. 
Mean plasma testosterone and LH concentrations were not different between 
normal and poor semen quality stallions.  This means that circulating testosterone 
concentrations are not different due to the fertility of the animal and cannot be used as an 
indicator of fertility.  Mean plasma FSH concentration had a tendency to be higher in 
poor semen quality stallions and mean plasma IGF-I had a tendency to be lower in poor 
semen quality stallions.  First, Jan Roser’s lab reported an increase in LH and FSH 
concentration in subfertile stallions (Roser and Hughes, 1992) then no difference in FSH 
concentration due to subfertility (Motton and Roser, 1997), however they indicated that 
plasma IGF-I concentration was directly related to declined fertility in stallions (Hess and 
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Roser, 2001).  Further studies are necessary in order to determine if these hormones are 
different as a result of poor semen quality or if they are just due to the low number of 
stallions used in this study.   
Mean plasma estradiol and immunoreactive (ir)-inhibin concentrations were 
significantly lower in poor semen quality stallions than in normal stallions.  The decrease 
of estradiol found in poor semen quality stallions is contrary to previous work by Jan 
Roser; however, decline in ir-inhibin in subfertile stallions was noted in previous studies 
(Motton and Roser, 1997).  Other investigators have indicated that estradiol is an 
important hormone in the regulation of stallion reproductive function (Roser, 2001).  
These results would support that hypothesis.  Plasma estradiol concentration was 
correlated with total PAR WT (r=0.8641; P<0.0013), DSPH (r=0.8047; P<0.0050) and 
DSO (r=0.6876; P<0.0194) and inversely correlated with mean apoptotic rate (r=-0.6791; 
P<0.0216).  Plasma inhibin concentration was correlated with total PAR WT (r=0.7753; 
P<0.0084), DSPH (r=0.7528; P<0.0120) and DSO (r=0.6863; P<0.0197) and inversely 
correlated with mean apoptotic rate (r=-0.6629; P<0.0262).  Plasma inhibin has been 
identified as a useful indicator of stallion reproductive activity (Nagata et al., 1998a).   
The results of our research indicate that plasma inhibin concentration is more useful as an 
indicator of stallion fertility than plasma testosterone concentration. 
In vitro culture techniques were utilized to determine if poor semen quality 
stallions suffer from receptor-mediated or non-receptor mediated inhibition.  HCG 
treatment was employed to test the receptor-mediated pathway.  Testosterone output was 
not statistically different between poor semen quality and normal stallions following hCG 
treatment in vitro due to a high standard deviation but numerical differences were 
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present.  Forskolin treatment was utilized to test the non-receptor mediated pathway of 
testosterone production.  Testosterone response to forskolin treatment in vitro had a 
tendency to be lower in poor semen quality stallions.  Future investigation is needed to 
identify if results were due to small number of animals.  Testis content of StAR protein 
after hCG treatment did not differ between poor semen quality and normal stallions.  
Previous reports had indicated a change in StAR mRNA with hCG treatment (Kerban et 
al., 1999).  We were unable to detect changes in StAR protein expression with hCG 
treatment in the testis.  Also, basal expression of StAR and P450scc proteins were not 
different between normal and poor semen quality stallions.  This indicates that StAR 
transport of cholesterol and P450scc cleavage of cholesterol to pregnenolone do not result 
in stallion poor semen quality in the animals studied. 
These data provide information useful in future research for studying poor semen 
quality in stallions.  Future investigation is needed in order to identify causes of poor 
semen quality as well as select testicular or hormonal parameters useful in diagnosing 
poor semen quality stallions.   
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CHAPTER VI 
SUMMARY AND CONCLUSIONS 
This project was conducted to 1) add important endocrine genes to the horse 
chromosome map, 2) determine gene expression patterns in the testis of normal and poor 
semen quality stallions and 3) determine hormonal and seminal parameter changes 
associated with fertility.  The animals in this research study consisted of a normal group 
and poor semen quality group of stallions.  One flaw in this research project was that 
experimental design was not optimal.  The stallions used were not all castrated in the 
same breeding season.  Plus, the stallions were not all the same breed, which means that 
genetics could have affected semen quality.  The stallions in the poor semen quality 
group of animals were considered to have had poor semen quality for a variety of 
biological reasons.  The poor semen quality animals were not a uniform group, which 
created a large standard deviation in experimental results. 
It is difficult to classify stallions into groups predicted to be either:  a) fertile, b) 
subfertile or c) infertile when one attempts to compare data from different investigators.  
There appear to be hormonal differences in these three categories of stallions that would 
be useful as indicators of fertility.  More consistent criteria of fertility are needed in order 
to define these groups for future research. 
The following parameters differed between normal and poor semen quality 
stallions:  LT PAR WT, RT PAR WT, total PAR WT, LT DSP/g, RT DSP/g, mean 
DSP/g, LT DSPT, RT DSPT, DSPH, DSO, motility, PMS, MNS, LT apoptotic rate, RT 
apoptotic rate and mean apoptotic rate.  Apoptotic rate was inversely correlated with all 
PAR WT measurements and DSP parameters.  This information suggests that the amount 
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of apoptosis or cell death that takes place in the stallion testis is directly related to the size 
of the testes.  Because of this, scrotal width measurements taken when performing BSE 
evaluations on stallions can be a useful tool in predicting apoptotic rate, DSP, DSO, 
motility, PMS and MNS.  In order for this to be effective, future studies need to be 
performed to determine the relationship between scrotal width and parenchymal weight. 
Many important genes in the stallion testis were evaluated in this study by gene 
expression.  StAR protein was localized in Leydig cells in the interstitial space of the 
stallion testis by in situ hybridization (ISH), as expected from work in other species.  
StAR protein is important for cholesterol transport from the outer mitochondrial 
membrane to the inner mitochondrial membrane for steroid biosynthesis (Pollack et al., 
1997).  The amount of StAR protein mRNA and StAR protein protein in the testis did not 
differ between normal and poor semen quality stallions.  Also, StAR protein expression 
in the testis in response to hCG stimulation in vitro did not differ between normal and 
poor semen quality stallions.  P450scc protein expression in the testis was not different 
between normal and poor semen quality stallions.  The content of StAR protein was 
correlated with P450scc protein in the testis among all stallions (r=0.6217; P<0.00233).  
Gonadotropins and androgens as well as their receptors in the testis are known to 
be important factors that can impact male fertility.  Circulating testosterone 
concentrations are readily available through RIA methodology as a diagnostic tool, 
however plasma testosterone concentration did not differ between normal and poor 
semen quality stallions.  Also, testosterone output in the testis with hCG treatment in 
vitro did not differ between normal and poor semen quality stallions.  Testosterone 
response of parenchyma in cultures to forskolin treatment tended (P<0.10) to be lower in 
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poor semen quality stallions than normal stallions.  Motton and Roser (1997) reported no 
difference in testosterone concentration in poor semen quality stallions compared to 
normal stallions, however they had a decrease in testosterone concentration in infertile 
stallions.  These data indicate that circulating testosterone concentration is adequate in 
poor semen quality stallions.  Likewise, in our experiments, plasma LH concentration and 
LHR mRNA expression did not differ between normal and poor semen quality stallions.  
Plasma FSH tended (P<0.10) to be higher in poor semen quality stallions than normal 
stallions, but FSHR mRNA expression did not differ between the two groups.  First, 
Roser’s lab reported an increase in LH and FSH concentration in subfertile stallions 
(Roser and Hughes, 1992) and secondly, no difference in LH and FSH concentrations in 
subfertile animals compared to fertile, but a decrease in LH and FSH in infertile stallions 
(Motton and Roser, 1997).  Further investigation is needed to determine if there are 
changes in LH and FSH concentrations in poor semen quality stallions. 
Androgens have also been identified as important hormones for testicular 
function.  In our study, AR was detected by ISH and slot blot mRNA techniques in the 
stallion testis.  AR mRNA expression in the testis did not differ between normal and poor 
semen quality stallions.  Testosterone concentration was inversely correlated with AR 
mRNA expression in the testis (r=-0.7907; P<0.0022). 
In recent years, estrogen has also been identified in the testis and is thought to 
play an important role in testis function.  In our study, ER alpha mRNA expression 
tended (P<0.10) to be higher in poor semen quality stallions than normal stallions, while 
ER beta mRNA expression was decreased in poor semen quality stallions.  Plasma 
estradiol concentration was lower in poor semen quality stallions than normal stallions.  
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Plasma estradiol was correlated with plasma inhibin concentration (r=0.9391; P<0.0001) 
as well as parenchymal weight, DSP, DSO, motility, PMS and MNS among all stallions 
(correlation values stated previously).  ER alpha mRNA expression was inversely 
correlated with ER beta mRNA expression among all stallions (r=-0.6162; P<0.0249).  
While ER alpha knockout mice are completely infertile, ER beta knockout mice appear to 
have no compromised fertility (Couse et al., 2001).  This could indicate that the presence 
of estrogen in the stallion testis is crucial for fertility, but the varying importance of the 
two isoforms remains unknown.  Further studies are necessary in order to elucidate the 
different roles of ER alpha and ER beta in the stallion testis. 
Since glucocorticoids are sometimes used for therapeutic treatment of stallions, 
our research included the GR as an important gene to study in the testis.  In our research, 
GR alpha, GR beta and GR exon 2 were detected by RPA, ISH and slot blot mRNA 
techniques in stallion testis.  ISH for AR, GR alpha, GR beta and GR exon 2 will need to 
be repeated in the future to identify localization of these mRNAs in various cell types of 
the testis.  GR alpha and GR exon 2 mRNA expression did not differ between normal and 
poor semen quality stallions.  ISH and mRNA results demonstrate the presence of both 
GR alpha and GR beta isoforms in the stallion, as observed in the human and rat testes 
but not the mouse where GR beta is absent.  The presence of GR beta in the stallion was 
unknown previously since the synteny of GR beta is not conserved across species and is 
absent in the mouse (Otto et al., 1997).  The quantity of GR beta mRNA in stallion testes 
tended to be lower in poor semen quality stallions.  Further studies are necessary to 
determine the physiological significance of GR beta in the stallion testis and the 
functional role of GR beta in spermatogenesis and steroidogenesis. 
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Somatogenic/lactogenic hormones have also been identified in the testis and their 
role in testicular function is still under investigation.  In our study, IGF-I and IGF-II 
mRNA expression did not differ between normal and poor semen quality stallions. The 
expression of PRLR, GHR and IGF-IR mRNAs were all lower in poor semen quality 
stallions than normal stallions.  Plasma IGF-I tended to be lower in poor semen quality 
stallions than normal stallions.  Plasma IGF-I was correlated with total parenchymal 
weight (r=0.06111; P<0.0348), DSPH (r=0.6772; P<0.0156) and MNS (r=0.5776; 
P<0.0492).  Hormones such as prolactin, growth hormone and IGF-I appear to play an 
important autocrine/paracrine role in the testis (Welsh et al., 1986; Spiteri-Grech and 
Nieschlag, 1993; Gnessi et al., 1997; Schlatt et al., 1997).  IGF-I may be a local 
modulator of testicular function in the stallion since IGF-I has been shown to stimulate 
the proliferation of Sertoli cells and spermatogonia through the IGF-IR (Jaillard et al., 
1987; Soder et al., 1992).  Also, GHR knockout mice were shown to have reduced 
fertility (Chandrashekar et al., 1999) and similarly poor semen quality stallions in this 
study had a reduced GHR mRNA expression.  Further investigation is needed in the 
stallion to determine the affects of PRLR, GHR and IGF-IR expression on stallion 
fertility. 
Other investigators have indicated inhibin to be a good indicator of stallion 
fertility (Roser, 2001).  We included inhibin in our study to determine if the hormone 
would be a good indicator of fertility as well as infertility.  In our study, βB inhibin 
mRNA expression and plasma ir-inhibin concentration was lower (P<0.05) in poor semen 
quality stallions than normal stallions.  Plasma ir-inhibin was correlated with 
parenchymal weight, DSP, DSO, motility, PMS and MNS among all stallions (correlation 
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values stated previously).  Kolb et al. (2000) and Yalti et al. (2002) reported inhibin 
concentration was correlated with sperm production in the human testis.  The same 
results were found in the stallions in this study.  Plasma inhibin concentrations have been 
reported to be lower in elderly men (Mahmoud et al., 2003).  Plasma ir-inhibin 
concentration was also reported to be lower in poor semen quality stallions than normal 
stallions (Stewart and Roser, 1998).  Since inhibin is an important regulator of 
gonadotroph secretion and paracrine regulation of testicular function (Marchetti et al., 
2003), changes in inhibin secretion might be an indicator of fertility status (von 
Eckardstein et al., 1999; Hu et al., 2003).  Plasma inhibin results indicate that inhibin 
concentration is a useful and non-invasive method for the evaluation of male subfertility 
and is correlated with sperm production (Stewart and Roser, 1997; Yalti et al., 2002).  
Further investigation is needed to determine if plasma inhibin concentration can be used 
as a tool for identifying male fertility status. 
We have now placed two important endocrine genes on the horse cytogenetic 
map. LHR maps to the same chromosome that contains follicle-stimulating hormone 
receptor (FSHR) (Chowdhary et al., 2002).  Equine glucocorticoid receptor mapped to 
chromosome 14q16-q21, a gene poor region in need of further cytogenetic mapping data.  
Equine luteinizing hormone receptor mapped to chromosome 15q22-q23.  By 
identification of the chromosomal location of GR we have also added information to a 
gene poor region of the ECA 14 map.  Equine specific probes are now available for 
clarification of the role of LHR in reproduction, and primers that amplify the GR isoforms 
are available for use in gene expression studies of glucocorticoid resistance.  The 
chromosomal locations of LHR and GR are now available for further study of infertility 
 
 120
or genetic diseases associated with glucocorticoids.  Polymorphisms in and around these 
genes could be studied in horse families to determine whether there are associations 
between these genes and infertility. 
This project was conducted to 1) add important endocrine genes to the horse 
chromosome map, 2) determine gene expression patterns in the testis of normal and poor 
semen quality stallions (Tables 4 and 5) and 3) determine hormonal and seminal 
parameter changes associated with semen quality.  As a result of this research, two 
important endocrine genes were added to the horse chromosome map.  StAR protein was 
localized to Leydig cells in the interstitial space of the stallion testis.  The AR and both 
isoforms of GR were detected in the stallion testis.  The presence of GR beta was proven 
and was unknown previously in the stallion.  The expression of PRLR, GHR and IGF-IR 
mRNAs were all lower in the testis of poor semen quality stallions compared to normal 
stallions.  ER beta mRNA expression and plasma estradiol concentration were 
significantly lower in poor semen quality stallions.  βB inhibin mRNA expression and 
plasma ir-inhibin concentration was lower in poor semen quality stallions than normal 
stallions.  This supports the concept that plasma inhibin concentration is one tool for 
determining male fertility status.  These data provide preliminary information and tools 
for future research to determine the gene expression and hormonal changes associated 
with stallion poor semen quality. 
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Table 4.  Gene expression results that did not differ between normal and poor semen 
quality stallions. 
 
mRNA Normal 
Stallion 
Mean 
(density of 
pixels) 
Normal 
Stallion 
Standard 
Deviation 
(density of 
pixels) 
Poor Semen 
Quality 
Stallion 
Mean 
(density of 
pixels) 
Poor Semen 
Quality 
Stallion 
Standard 
Deviation 
(density of 
pixels) 
P-value
FSHR 2.70x10e6 1.15x10e5 2.62x10e6 1.55x10e5 0.72 
LHR 2.52x10e6 1.49x10e5 2.38x10e6 2.01x10e5 0.64 
StAR 2.78x10e7 2.09x10e6 2.99x10e7 2.82x10e6 0.61 
GR alpha 1.09x10e6 3.12x10e4 1.12x10e6 4.21x10e4 0.69 
GR exon 2 4.29x10e6 1.48x10e5 4.15x10e6 2.00x10e5 0.63 
AR 3.75x10e6 7.88x10e4 3.77x10e6 1.06x10e5 0.91 
IGF-I 2.00x10e6 6.87x10e4 2.00x10e6 9.27x10e4 0.99 
IGF-II 3.56x10e7 1.40x10e6 3.71x10e7 1.90x10e6 0.58 
ER alpha 2.71x10e6 6.54x10e4 2.93x10e6 8.83x10e4 0.09 
GR beta 8.64x10e5 1.99x10e4 7.89x10e5 2.69x10e4 0.07 
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Table 5.  Gene expression results that differed between normal and poor semen quality 
stallions. 
 
mRNA Normal 
Stallion 
Mean 
(density of 
pixels) 
Normal 
Stallion 
Standard 
Deviation 
(density of 
pixels) 
Poor Semen 
Quality 
Stallion 
Mean 
(density of 
pixels) 
Poor Semen 
Quality 
Stallion 
Standard 
Deviation 
(density of 
pixels) 
P-value 
ER beta 1.84x10e7 7.53x10e5 1.39x10e7 1.02x10e6 0.01 
βB inhibin 2.61x10e7 9.86x10e5 2.18x10e7 1.33x10e6 0.04 
PRLR 6.73x10e7 1.57x10e6 5.80x10e7 2.12x10e6 0.01 
GHR 2.24x10e6 8.11x10e4 1.72x10e6 1.09x10e5 0.01 
IGF-IR 7.14x10e5 2.27x10e4 5.87x10e5 3.06x10e4 0.01 
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APPENDIX A 
 
FLUORESCENCE IN SITU HYBRIDIZATION (FISH) PROTOCOL 
 
Procedures described by Chowdhary et al. (2002, 2003) 
 
A.  Probe Preparation 
1.  Label probes with biotin by nick translation (BioNick Labeling System, Invitrogen         
Corp. cat# 18247-015). 
1 µg probe DNA 
5 µl 10X dNTP mix (T, G, C, bio-dATP) 
5 µl 10X enzyme mix (DNA Polymerase I and DNase I) 
dd water up to 45 µl 
2.  Mix reaction up and down with pipette and incubate at 16°C for 1 hour and 15 
minutes. 
3.  Purify the labeled probe through a Qiagen QIAquick PCR column (Qiagen, Inc., 
Valencia, CA). 
4.  Check the size and quantity of the labeled probe on a 1% agarose gel using 1 µl of 
labeled probe and 1 µl Orange G dye.  Use 100 bp marker (New England Biolabs, 
Beverly, MA) to identify size.  
5.  Run the gel at 100 volts for approximately 30 minutes.  The labeled probe should 
yield or result in a smear in the size range of 200 to 600 bp. 
 
B. Chromosome Slide Preparation 
1.  Under the microscope choose suitable hybridization area and mark it with a glass 
pencil on the opposite side of each slide by identifying dense regions of elongated 
chromosomes under the microscope. 
2.  Apply 500 µl of RNase working solution to the slide and cover slip the slide. 
3.  Incubate at 37°C for 1 hour. 
4.  Wash the slides in 2X SSC for a maximum of 5 minutes. 
5.  Pass the slides through the following washes: 
 70% ethanol  2 minutes 
 80% ethanol  2 minutes 
 90% ethanol  2 minutes 
 100% ethanol  2 minutes 
6.  Allow slides to air dry. 
 
C.  Hybridization 
1.  Make master mix of hybridization mix: 
 36 ml 100% formamide 
 7 g dextran sulfate 
 7.5 ml 20X SSC 
Mix and store in 200 µl aliquots at –20°C.  Mix 7:3 master mix to DNA for 
hybridization. 
 
 
 
 136
 
2.  Denature chromosomes in 70% formamide, 2X SSC at 70ºC for 2 minutes and 
immediately pass through ice cold ethanol series (70%, 80%, 90%, 100% at 2 minutes 
each).  Allow to air dry at room temperature. 
 70% Formamide, 2X SSC: 
 175 ml 100% formamide 
 25 ml 20X SSC 
 50 ml water 
 pH 7.0 with HCl; store at 4°C in dark. 
3.  Quickspin probe and transfer 3 µl to a new microfuge tube. 
4.  Denature probe at 70°C for 10 minutes. 
5.  Preanneal probe mix at 37°C for 20 minutes and quickspin. 
6.  Apply 2 to 4 µl of preannealed probe mix to chromosome slide.  Cover with a 
coverslip and seal the edges with rubber cement. 
7.  Place the slides in a moist chamber and incubate at 37°C overnight. 
 
D.  Washing and Signal Detection 
1.  Remove rubber cement with a needle and rinse slides in 2X SSC until coverslips come 
off. 
2.  Wash slides three times in 50% formamide, 2X SSC at 40-45°C for 5 minutes. 
3.  Wash slides three times in 4X SSC, 0.05% Tween20 at room temperature for 2 
minutes. 
4.  Wash slides once in 4X SSC at room temperature for 2 minutes. 
5.  Add 0.2 µl Avidin-FITC in 200 µl PNM Buffer to each slide.  Coverslip and incubate 
in a moist chamber for 30 minutes. 
6.  Wash slides three times in 4X SSC, 0.05% Tween20 at room temperature for 2 
minutes. 
7.  Wash slides once in 4X SSC at room temperature for 2 minutes. 
8.  Add 2 µl Biotinylated Anti-Avidin in 200 µl PNM buffer to each slide.  Coverslip and 
incubate for 30 minutes. 
9.  Wash slides three times in 4X SSC, 0.05% Tween20 at room temperature for 2 
minutes. 
10. Wash slides once in 4X SSC at room temperature for 2 minutes. 
11. Add 0.2 µl Avidin-FITC in 200 µl PNM buffer to each slide.  Coverslip and incubate 
for 30 minutes. 
12. Wash slides three times in 4X SSC, 0.05% Tween20 at room temperature for 2 
minutes. 
13. Wash slides once in 4X SSC at room temperature for 2 minutes. 
14. Apply 10-20 µl of DAPI/anti-fade solution to each slide and coverslip.  Keep slides in 
a dark box at 4°C. 
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E.  Solutions 
1.  PN buffer 
0.1 M Na2HPO4 X 2 H2O 
Adjust pH to 8.0 with 0.1 M monobasic NaH2PO4 X H2O 
 
2.  PNM buffer 
5% dry milk in 0.1 M PN buffer pH 8.0.  Dissolve overnight at 37°C then 
centrifuge in microfuge tube at max speed for 10 minutes.  Divide supernatant 
into 500-1000 µl aliquots and freeze. 
 
3.  20X SSC 
 88 g Sodium Citrate 
175 g Sodium Chloride 
Mix well and filter with 0.2 µm bottle top filter. 
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APPENDIX B 
 
RADIATION HYBRID  (RH) MAPPING PROTOCOL 
 
Chowdhary et al. (2002, 2003) 
 
1.  Optimize primers in horse genomic DNA ensuring that hamster genomic DNA is not 
amplified and primer amplification is horse specific. 
2.  Use the 5000rad whole-genome RH panel comprised of 92 hybrid cell lines to type 
each primer pair by PCR.  Make sure to include a ‘no-DNA’ control as well as horse 
and hamster genomic DNA for positive controls. 
3.  Resolve PCR products on a 2.5% agarose gel (containing 0.25 µg/ml ethidium 
bromide). 
4.  Manually score the gel results using 0, 1 & 2 to signify bands are either present (0), 
absent (1) or indistinguishable (2) for each lane of the gel and record results in 
Microsoft Excel spreadsheet. 
5.  Repeat steps 2 through 5 to repeat the RH panel typing and confirm results. 
6.  Use two-point linkage analysis to obtain nearest marker information with 1000:1 odds 
(or LOD 3). 
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APPENDIX C 
 
IN SITU HYBRIDIZATION (ISH) PROTOCOL 
 
A.  Probe Transcription 
1.  Place (anti-sense) DNA template gel chunks (bands cut from low-melt gel) at 70°C for 
10 minutes, then transfer to 37°C for use. 
2.  Mix the following reaction in order at room temperature for each sample: 
 
Reagent Volume
DEPC water 1.7 µl 
5X Transcription Buffer 4.0 µl 
1 M DTT 0.2 µl 
33 uM ACG nucleotides 0.3 µl 
100 uM UTP 0.5 µl 
RNasin 0.8 µl 
4 µl 35S UTP 4.0 µl 
DNA from gel chunk 4.0 µl 
RNA Polymerase enzyme 1.0 µl 
Total 20.0 µl 
 
3.  After addition of gel chunk, the reaction should stay at 37°C.  Mix the reaction 
thoroughly with pipette and incubate for 1 hour. 
4.  Remove 1 µl of the transcription reaction and add 9 µl of formamide.  Heat at 70°C 
for 10 minutes then load samples on the probe test gel.  Load 3 µl of dye marker in an 
extra well. 
5.  Run gel at 40 mAmps for 45 minutes. 
6.  Allow transcription reaction to continue for another hour. 
7.  Expose gel to XAR film for 1 hour or overnight. 
8.  Add 1 µl of RQ1 DNase to each transcription reaction.  Vortex samples and incubate 
at 37°C for 15 minutes. 
9.  Freeze the probes at –80°C overnight. 
 
B.  Probe Cleanup 
1.  Develop film and proceed with probe cleanup if all probes appear to have incorporated 
radioactivity. 
2.  Add 30 µl sterile water to each probe. 
3.  Phenol chloroform isoamyl (PCI) extract with 50 µl of PCI (pH 5.0).  Vortex and 
centrifuge at 10,000 rpm for 4 minutes. 
4.  Remove upper aqueous layer and add 50 µl of chloroform isoamyl (CI).  Vortex to 
mix and centrifuge at 10,000 rpm for 4 minutes. 
5.  Remove upper aqueous layer by pipetting. 
6.  Use Roche RNA MiniQuick Spin Columns (Roche, Switzerland) to cleanup probes.  
(Follow instructions to resuspend column and spin samples.) 
7.  Check probe counts using 1 µl of probe in scintillation fluid. 
8.  Heat probes at 68°C before use. 
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C.  Slide Preparation 
1.  Deparaffinize the sections by taking the slides through the following steps: 
 CitriSolv™ (Fisher Scientific) 2 minutes 
 100% Ethanol    2 minutes 
 100% Ethanol    2 minutes 
 95% Ethanol    2 minutes 
 70% Ethanol    2 minutes 
 50% Ethanol    2 minutes 
2.  Fix the sections in 4% paraformaldehyde for 10 minutes at 4°C. 
3.  Wash slides in 0.5X SSC for 5 minutes at room temperature. 
4.  Soak the slides in Proteinase K (20 µg/ml in RNase buffer) for 10 minutes at room 
temperature (RT). 
5.  Wash slides in 0.5X SSC for 10 minutes at room temperature. 
6.  Preheat Hybridization Buffer to 55°C. 
7.  Blot the slides dry and place them in tupperware or pyrex containers resting on plastic 
pipettes.  A paper towel soaked in box buffer is placed on the bottom of the container. 
8.  Circle tissue sections with rubber cement to form a reservoir for the probes. 
9.  120 µl is added to each section containing 500,000 counts of probe, 10% volume of 
1mM DTT, 2 µl/section of yeast tRNA and hybridization buffer.  The probe and yeast 
tRNA mixture is heated at 70°C for 5 minutes then placed on ice. 
10. The container with the slides is covered and the slides incubate overnight at 55°C. 
 
D.  Slide Washing 
1.  Heat a shaking water bath to 55°C.  Make 2 liters of 0.1X SSC, 10 mM 2-
mercaptoethanol (2-ME), 1 mM EDTA buffer and place slides in 55°C water bath. 
2.  Slides are placed in a rack and washed as follows (the waste is radioactive--use 
proper containers and disposal procedures): 
 A.  2X SSC with 10 mM 2-ME + 1 mM EDTA, 10 min., RT 
 B.  Repeat A 
 C.  20 µg/ml RNase A in RNase Buffer, 30 min., RT 
 D.  2X SSC with 10 mM 2-ME + 1 mM EDTA, 10 min., RT 
 E.  Repeat D 
 F.  0.1X SSC with 10 mM 2-ME + 1 mM EDTA, 1 hour, 55°C, gently shaking 
 G.  Repeat F 
 H.  0.5X SSC, 10 min., RT 
 I.  Repeat H 
3.  Dehydrate slides by placing through ethanol washes as follows: 
 50% Ethanol + 0.3 M NH4Ac, 2 min., RT 
 70% Ethanol + 0.3 M NH4Ac, 2 min., RT 
 90% Ethanol + 0.3 M NH4Ac, 2 min., RT 
4.  Remove the rubber cement by lifting the edge with a needle. 
5.  Blot slides dry on the edge and dry in racks on a tray for 1-to-3 hours at 37°C. 
6.  Line slides up in a film cassette.  Tape down the edges.  Expose to film 3-to-4 days at 
room temperature with the cassette wrapped in foil. 
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E.  Slide Dipping 
1.  If the film shows that the slides look “good,” then the slides are dipped in Kodak 
NTB2 nuclear emulsion in the dark room. 
2.  Emulsion is diluted 1:1 with water.  Emulsion should be at 42ºC in a water bath and 
poured into dipmizer. 
3.  First a blank slide is dipped and developed to test the emulsion quality (Developer 5 
min., water 30 sec., Fixer 5 min. and running water 5 min.). 
4.  Dip experimental slides in emulsion at 42ºC and lean them at a diagonal on a slide box 
to dry.  Transfer the slides to a slide box containing fyrite wrapped in a kimwipe. 
5.  Dry slides in the bread box for 2 hours without the lid. 
6.  Wrap slide boxes with foil and place at 4ºC until time to develop. 
 
F.  Slide Development 
1.  Place slides in Kodak Developer diluted 1:1 with water and at 15ºC for 4 minutes in 
the dark room. 
2.  Place slides in distilled water for 30 seconds. 
3.  Place slides in Kodak Fixer with Hardener for 5 minutes. 
4.  Place slides under running water for 5 minutes. 
5.  Slides can be brought out of the dark room but must be kept wet. 
6.  Stain slides using 1% Toludine Blue stain (made in Boric Acid) for 4 minutes. 
7.  Wash slides with water for 30 seconds. 
8.  Place slides in 50% Ethanol for 3 minutes. 
9.  Place slides in 70% Ethanol for 2 minutes. 
10. Place slides in 95% Ethanol for 2 minutes. 
11. Place slides in 100% Ethanol for 1 minutes. 
12. Place slides in Xylene for 1 minute. 
13. Use Permount to cover slip slides. 
14. Allow slides to dry for 3 days then clean up slides using Xylene. 
 
G.  Recipes for in situ hybridization solutions 
1.  20X SSC 
 173 g Sodium Chloride 
 88.2 g Sodium Citrate 
Bring up to 1 liter with distilled water.  Add 1 ml Diethyl Pyrocarbonate (DEPC) 
and shake vigorously.  Place at 37ºC overnight.  Autoclave for 40 minutes. 
 
2.  0.5X SSC 
 25 ml 20X SSC 
 975 ml DEPC water 
 
3.  4% paraformaldehyde (200 ml) 
In a fume hood, heat 100 ml of nanopure water in a beaker and stir in 8 g of 
paraformaldehyde.  Add 1-2 drops of 2 M NaOH and the solution should clear.  
Remove from heat and add 66 ml of 3X PBS.  Adjust pH to 7.4 with HCl and 
bring up to 200 ml with distilled water. 
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4.  2X SSC with 10 mM 2-ME + 1 mM EDTA 
 100 ml 20X SSC 
 77 µl 13 M 2-ME 
 2 ml 0.5 M EDTA 
 Bring to 1 liter with DEPC water. 
 
5.  0.1X SSC with 10 mM 2-ME + 1 mM EDTA 
 10 ml 20X SSC 
 154 µl 13 M 2-ME 
 4 ml 0.5 M EDTA 
Bring to 2 liters with DEPC water. 
 
6.  RNase Buffer (500 mM NaCl, 10 mM Tris) pH 8.0 
 50 ml 5 M NaCl 
 5 ml 1 M Tris, pH 8.0 
 445 ml Nanopure water 
 
7.  Box Buffer (4X SSC + 50% formamide) 
 100 ml 20X SSC 
 250 ml formamide 
150 ml DEPC water 
 
8.  Hybridization Buffer 
 25 ml Formamide 
 6 ml 2.5 M NaCl 
 1 ml 1 M Tris, pH 8.0 
 0.5 ml 0.5 M EDTA 
 1 ml 0.5 M sodium phosphate, dibasic 
 5 g Dextran sulfate 
 1 ml 50X Denhardt’s 
 5 ml DEPC water 
Incubate at 37ºC on a rocker for 4 hours to dissolve.  Add 1/10 volume 1M DTT 
immediately prior to use. 
 
9.  50X Denhardt’s (to 500 ml with DEPC water) 
5 g Ficoll 400 
5 g Polyvinylpyrrolidone  
5 g BSA (Pentax Fraction V) 
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APPENDIX D 
 
RNA EXTRACTION PROCEDURE 
 
 
** Always wear gloves! 
1.  Pipette 3 ml of TriPure (Roche, Switzerland) into 50 ml conical tubes.  One tube for 
each tissue sample.  Keep tissue and samples on ice. 
2.  Place vials of tissue on ice.  Transfer ~ 0.3 g of tissue to designated 50-ml conical 
tube. 
3.  Record the weight of each amount of tissue used. 
4.  Wash tissue homogenizer with ddH2O thoroughly before use. 
5.  Homogenize each tissue in 50-ml conical tubes for 30 seconds.  Go back through 
samples a second time and homogenize again for 30 seconds.   
* Clean homogenizer between each sample with two different containers of ddH2O.  
Wipe off excess water with Kimwipes.  ** Keep tissue on ice. 
6.  Can keep tissue at 4°C overnight at this point and finish extraction procedure the next 
day. 
7.  Let samples sit at room temperature for 5 minutes. 
8. Under the fume/solvent hood add 600 µl of chloroform to homogenized tissue.  Vortex 
and transfer each sample to RNAse Zap treated plastic tubes properly labeled.  (Color 
change seen from clear to opaque.) 
9.   Incubate samples for 2-to-15 minutes at room temperature. 
10. Spin for 15 minutes at 12,000 rpm at 4°C. 
11. Remove top layer of RNA with pipette and transfer to new plastic tube (treated with 
RNAzap).  Stay away from the white DNA layer. 
12. Add 1.5 ml of isopropanol to each sample.  Vortex and incubate for 10 minutes at 
room temperature. 
13. Centrifuge at 12,000 rpm for 10 minutes at 4°C. 
14. Remove supernatant and discard. 
15. Add 3 ml of 70% ethanol made with DEPC ddH2O. 
16. Vortex until pellet floats.  Spin at 12,000 rpm for 10 minutes at 4°C. 
17. Remove Ethanol and discard.  Allow pellets to dry.  Should use Kimwipe tissue paper 
to wipe tube dry. 
18. Resuspend pellets in 100 µl of DEPC ddH2O. 
19. Incubate at 68°C for 10 minutes. 
20. Collect volume into 1.5 ml microfuge tubes.  Aliquot 3 µl of sample to run 1.5% 
Agarose denaturing gel and 5 µl of sample diluted in 995 µl of DEPC ddH2O to spec 
concentration. 
21. Store RNA samples at –80°C.  Minimize number of thaws and time spent on ice to 
prevent degradation. 
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APPENDIX E 
 
RIBONUCLEASE PROTECTION ASSAY (RPA) PROTOCOL 
 
A.  Gel Preparation 
1.  Clean one short and one long sequencing plate by washing with Alconox detergent 
and rinsing with tap water. 
2.  Clean plates with RNazap (Ambion, Inc., Austin, Texas). 
3.  Clean plates with DEPC water. 
4.  Clean plates with 100% ethanol. 
5.  Clean plates with DEPC water. 
6.  Allow plates to dry. 
7.  Wipe short plate with Sigmacote (Sigma) and allow to dry. 
8.  Assemble plates with spacers on each side and rubber clamp around outside edge. 
9.  Prepare gel using the following recipe: 
 8.85 ml 40% Acrylamide 
 9.31 ml 2% Bis-acrylamide 
 7.45 ml 10X TBE 
 35.82 g Urea 
Mix the above ingredients with stir bar in RNazap treated glassware.  Apply low heat 
and spin until in solution.  Bring volume to 75 ml with DEPC water.  Place gel 
mixture on ice and allow to cool.  When ready to pour gel, add 450 µl of 10% 
Ammonium Persulfate (freshly made) and 60 µl of Temed.  Gently swirl mixture and 
pour gel. 
10. Make sure no bubbles are present in the gel.  Place the comb in between the plates 
and clamp the comb and the plates together. 
11. Allow the gel to solidify for two hours before removing the clamps and the comb. 
12. Pre-run the gel in 1X TBE buffer at 50 watts for 20 minutes before loading the 
sample probes for gel purification. 
 
B.  Probe Synthesis 
1.  Thaw the frozen reagents from Ambion MAXIscript in vitro transcription kit (cat# 
1312; Ambion, Inc., Austin, Texas). 
2.  Assemble the following transcription reaction at room temperature.  Heat DNA 
template gel chunks at 70°C for 10 minutes, then transfer to 37°C for sample 
removal. 
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Component Sample (µl) Century Marker (µl) 
cDNA Template 1.0 1.0 
Nuclease-free water 15.25 10.0 
10X Transcription Buffer 3.5 2.0 
10 mM ATP 1.75 1.0 
10 mM CTP 1.75 1.0 
10 mM GTP 1.75 1.0 
10 mM UTP 0 0 
10 mM 32P UTP 8.0 2.0 
T7 RNA Polymerase 2.0 2.0 
TOTAL 35 µl 20 µl 
 
3.  Mix all reactions gently.  Incubate reactions at 37°C for one hour. 
4.  Add 1.0 µl of DNase 1, mix well and incubate at 37°C for 15 minutes. 
5.  Add 1.0 µl of 0.5M EDTA and 30 µl of gel loading dye.  For marker, remove 1.5 µl of 
reaction and add 8 µl of gel loading dye. 
6.  Heat samples at 90°C for 3 minutes before loading on pre-run gel. 
7.  Run gel at 50 watts for approximately one hour. 
8.  Gently pull plates apart and cover gel on long plate with saran™ wrap.  Place XAR 
film on top of saran™ wrap and expose for 2-5 minutes. 
9.  Use film to mark probe bands on back of glass plate. 
10. Cut out probe bands from gel and place in 50 ml tube containing 300 µl of Elution 
buffer. 
11. Place probes at 37°C for at least one hour. 
12. Count 1 µl of probe using Beta Counter. 
 
C.  Ribonuclease Protection Assay 
1.  Thaw the frozen reagents from the Ambion RPA III kit (cat# 1414; Ambion, Inc., 
Austin, Texas). 
2.  Mix 20 µg of sample RNA and 100,000 counts of labeled probe. 
3.  Set up yeast A and yeast B control tubes containing 4 µl of yeast RNA and the same 
volume of probe as the RNA samples. 
4.  Co-precipitate the probes and sample RNA using 1/10 reaction volume of NH4OAc 
and 2.5 volumes of cold 100% ethanol. 
5.  Place tubes in –20°C for at least 15 minutes. 
6.  Centrifuge samples at max speed (10,000 rpm) for 15 minutes. 
7.  Pipette off supernatant and air dry the pellets for at least 5 minutes. 
8.  Resuspend pellets with 10 µl Hybridization buffer and quick-spin tubes. 
9.  Heat samples at 90-95°C for 3-4 minutes. 
10. Incubate samples at 42°C overnight. 
11. Make 1:100 dilution of RNase A/T1 in RNase Digestion III buffer calculating enough 
mix to add 150 µl to each sample EXCEPT for the yeast B control. 
12. Quick-spin the samples and add 150 µl of the above mixture. 
13. Vortex and quick-spin samples. 
14. Incubate samples at 37°C for 30 minutes. 
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15. Add 1µl of yeast RNA to all samples. 
16. Add 225 µl RNase Inactivation/Precipitation III Solution to each sample. 
17. Add 75 µl of cold 100% ethanol to each sample. 
18. Place samples at –20°C for 15 minutes. 
19. Centrifuge samples at maximum speed (10,000 rpm) for 15 minutes at 4°C. 
20. Remove supernatant and allow samples to dry very well. 
21. Resuspend samples with 6 µl of gel loading dye. 
22. Heat all samples (including the marker) at 90°C for 3 minutes. 
23. Load samples on 5% acrylamide gel and run gel at 50 watts for 2 hours. 
24. Separate plates and place 3 mm Whatman filter paper (cat# 28458-005; VWR, West 
Chester, PA) cut to the gel size on top of the gel.  Roll a 50 ml tube on top of the 
Whatman paper until the gel can be pulled off of the plate. 
25. Cover the gel and Whatman paper with saran™  wrap and dry the gel on a pre-
warmed apparatus for 15 minutes. 
26. Tape the gel into a film cassette and expose to XAR film for 1-3 days at –80°C until a 
good image is acquired. 
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APPENDIX F 
 
SLOT BLOT PROCEDURE FOR mRNA ANALYSIS 
 
A.  Membrane Preparation 
1.   Clean all components of slot blot apparatus with RNAzap (Ambion).  Rinse well with 
DEPC water. 
2.   Use 20 µg of RNA per slot.  (If RNA sample is too dilute, then precipitate RNA using 
1/10 volume 3M NaOAc and 3 volumes 100% EtOH.  Mix well and place at –80ºC 
for 20 minutes.  Centrifuge at 10,000 x g for 10 minutes at 4ºC.  Pour off supernatant.  
Quick spin and pipet off remaining EtOH.  Reconstitute pellet in 10 µl of DEPC 
water.) 
3.   Wet a piece of nylon transfer membrane (Schleicher and Schuell, Keene, NH) briefly 
in water and soak in 20X SSC for 1 hour at room temperature. 
4.   Place two sheets of Whatman 3mm paper pre-wet with 20X SSC on top of the base 
(vacuum unit) of the slot blot apparatus.  Place the wet nitrocellulose on top of the 
blotting paper, and smooth out any air bubbles.  Clamp on the top of the apparatus 
and hand tighten screws in a diagonal fashion if using Bio-RAD. 
5.   Fill all slots with 10X SSC and apply gentle suction until the fluid has passed through 
all slots.  Turn off the vacuum and refill each slot.  NOTE:  Filter 20X SSC and 10X 
SSC solutions with a 0.2 µm filter to prevent clogging. 
 
Preparation of RNA Samples 
 
6.   Add the following to each 10 µl (20 µg) of RNA sample.  Use DEPC water if 
necessary to q.s. each sample to 10 µl total volume. 
 
 Formamide (100%)  20 µl 
 Formaldehyde (37%)    7 µl 
 20X SSC     2 µl 
 
7.   Mix well and denature samples at 70ºC for 15 minutes.  Cool on ice for 5 minutes. 
8.   Add 2 volumes (80 µl) of 20X SSC to each sample.  Mix well and centrifuge briefly.  
Keep on ice. 
9.   Remove 10X SSC from slot blot apparatus with gentle suction.  Turn off vacuum. 
10. Load samples into slots and apply gentle suction.  After samples have passed through, 
rinse each slot twice with 10X SSC.  Continue suction until all wells are dry. 
11. Remove filter from apparatus and allow to dry completely at room temperature.  Bake 
at 80ºC for 2 hours.  Store at –20ºC for up to 6 months. 
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B. Northern and Slot Blot Hybridization with cRNA Probes 
1.   Make hybridization buffer: 
 
 Concentration    for 100 ml
 5X SSC    25 ml of 20X SSC 
 5X Denhardt’s   10 ml of 50X Denhardt’s 
 50% Formamide   50 ml Formamide 
 1% SDS    10 ml of 10% SDS 
 DEPC water    5 ml DEPC water 
 100 µg/ml Salmon Sperm DNA 2 ml of 10 mg/ml stock 
 
NOTE:  Before use, denature salmon sperm DNA for 5-10 minutes at 95-100ºC.  
Add directly to hybridization buffer before use. 
 
2.   Wet nylon membrane briefly with 2X SSC. 
3.   Place membrane in hybridization buffer (~20 ml for medium tubes) in roller tubes.  
Prehybridize at 55ºC for 1 hour. 
4.   Synthesize antisense cRNA probe from antisense DNA with Ambion Maxiscript kit. 
 
 Component   Amount/probe
 Nuclease-free water  qs to 20 µl 
 DNA template         1 µg 
 10X Transcription Buffer       2 µl 
 10 mM ATP         1 µl 
 10 mM CTP         1 µl 
 10 mM GTP         1 µl 
 10 mM UTP         ---- 
 32P labeled UTP        5 µl 
 RNA Polymerase        2 µl 
 
Mix all ingredients above in 1.5-ml microfuge tubes for each probe needed.  
Incubate probes to synthesize at 37ºC for 1 hour.  Add 80 µl of DEPC water to 
each probe.  Extract with equal volume of Phenol, Chloroform, Isoamyl Alcohol 
(24:25:1).  Vortex and spin for 2 minutes at max speed.  Transfer top layer to new 
microfuge tube.  Add equal volume of chloroform, vortex and spin for 2 minutes 
at max speed.  Transfer top layer to new microfuge tube.  Column purify each 
probe and count 2 µl on liquid scintillation counter. 
 
5.   Add 500 µl of hybridization buffer to microfuge tube containing desired amount of 
radiolabeled antisense cRNA probe.  Usually desire 1 x 106 cpm/ml hybridization 
buffer. 
6.   Denature probe at 70ºC for 5-10 minutes.  Place on ice for 2 minutes. 
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7.   Add probe to hybridization buffer in roller tube and hybridize overnight (12-16 hours) 
at 55ºC.  Use as little of the hybridization buffer as necessary to ensure complete 
coverage of the blot during hybridization.  For medium tubes, 10-to-12 ml should be 
enough—remove extra buffer before addition of probe. 
8.   Prepare washes in advance and warm to desired temperature. 
9.   Wash the blot with 50 ml of 2X SSC/0.1% SDS at room temperature for 20 minutes. 
10. Wash the blot with 50 ml of 1X SSC/0.1% SDS at 55ºC for 20 minutes. 
11. Wash the blot 3 times with 50 ml of 0.1X SSC/0.1% SDS at 68ºC for 20 minutes 
each. 
12. Wash blot 3 times with 2X SSC for 5 minutes each (to remove SDS and fomamide). 
13. Incubate blot in 2X SSC containing 1 µg/ml RNAse A for 15 minutes at room 
temperature. 
14. Wash blot twice in 0.2X SSC/0.1% SDS at 55ºC for 15 minutes each. 
15. Wrap blot in saran wrap. 
16. Expose blot to autoradiography.  Either use phosphorimager or expose to film 
overnight at –80ºC. 
 
C.  Solutions 
 
1.  50X Denhardt’s (500 ml) 
5 g Ficoll 400 
5 g Polyvinylpyrrolidone  
5 g BSA (Pentax Fraction V) 
DEPC Water 
 
2.  20X SSC (1L) 
88 g Sodium Citrate 
175 g Sodium Chloride 
Mix well and filter with 0.2 µm bottle top filter. 
 
3.  10X SSC (1L) 
44 g Sodium Citrate 
87.5 g Sodium Chloride 
Mix well and filter with 0.2 µm bottle top filter. 
 
4.  2X SSC (500 ml) 
50 ml of 20X SSC bring to volume with DEPC water. 
 
5.  10% SDS (250 ml) 
25 g Sodium Dodecyl Sulfate (Laural Sulfate) 
Mix and bring to volume with DEPC water. 
 
6.  2X SSC/0.1% SDS (500 ml) 
50 ml of 20X SSC 
500 µl 10% SDS 
Bring to volume with DEPC water. 
 
 150
 
7.  1X SSC/0.1% SDS (500 ml) 
25 ml of 20X SSC 
500 µl 10% SDS 
Bring to volume with DEPC water. 
 
8.  0.1X SSC/0.1% SDS (500 ml) 
2.5 ml of 20X SSC 
500 µl 10% SDS 
Bring to volume with DEPC water. 
 
9.  0.2X SSC/0.1% SDS (500 ml) 
5 ml of 20X SSC 
500 µl 10% SDS 
Bring to volume with DEPC water. 
 
10. RNAse A 
10 mM Tris 
15 mM NaCl 
Mix and boil for 10 minutes.  Store at –20ºC. 
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APPENDIX G 
 
INSULIN-LIKE GROWTH FACTOR TYPE I (IGF-I) ASSAY PROTOCOL  
 
FOR BOVINE SERUM 
 
Reagent Preparation 
 
1.  IGF-I Assay Buffer 
 0.40 g Protamine (grade II) SO4 (Sigma P-4380) 
 8.28 g Sodium phosphate (monobasic) (Sigma S-9638) 
 1.0 ml Tween 20 (Sigma P-1379) 
 0.40 g Sodium azide (Sigma S-2002) 
 7.44 g EDTA 
 
Mix above reagents in double-distilled water (ddH20).  pH solution to 7.5 with 
NaOH and bring volume to 2.0 liters.  Store solution at 4ºC for one month.  
(Caution:  Sodium azide is highly toxic.) 
 
2.  1M Glycine 
 75.07 g Glycine (Sigma S-7126) 
Mix glycine in approximately 850 ml ddH20.  Using 38% HCl, adjust pH of 
solution to 3.2 and bring volume to 1.0 liter.  Make fresh 1M glycine for each 
extraction and store at 4ºC. 
 
3.  0.5N NaOH 
Add 50 ml of 2.5N NaOH to 200 ml ddH20 (1:5 dilution) or dissolve 5.0 g NaOH 
pellets into 250 ml ddH20.  Store at 4ºC. 
 
4.  12.5% Polyethylene Glycol (PEG) 
 250 g Carbowax PEG 8000 (Fisher P1567-500) 
Mix PEG in approximately 1800 ml ddH20, cover and mix at room temperature 
until solution is clear (2 hours).  Adjust pH of solution to 8.6 and bring volume to 
2.0 liters.  Store at 4ºC for up to 3 months. 
 
5.  Primary Antibody (Bovine IGF-I antibody for RIA) 
(Source:  A. F. Parlow, National Hormone and Peptide Program, Harbor-UCLA 
Medical Center, 1000 West Carson St., Torrance, CA  90509; Phone #:  
310.222.3537) 
 
Antibody comes lyophilized at a 1:10 dilution in PBS.  Use antibody at a final 
dilution of 1:120,000 in IGF-I Assay Buffer (7.5 µl stock into 90 ml IGF-I Assay 
Buffer).  Prepare fresh daily at least one hour before use and store at 4ºC. 
 
6.  Secondary Antibody (GARGG) 
 (Source:  Calbiochem, San Diego, CA; Goat Anti-Rabbit SA IgG) 
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Add 667 µl of stock GARGG to 39.33 ml IGF-I Assay Buffer (1:60 dilution).  
Prepare fresh daily and store at 4ºC. 
7.  Normal Rabbit Serum (NRS) 
Prepare at 1:100 dilution in IGF-I Assay Buffer (500 µl stock into 49.5 ml 
Buffer). 
 
8.  [125I] Tracer 
 (Source:  ICN Biomedicals Inc., Cat# 68128) 
 
Calculation of required activity: 
1µCi isotope = 22.20 x 106 dpm.  
2.22 x 106 dpm = 1.665 x 106 cpm (At 75% counting efficiency estimate [125I]). 
 
(n) RIA tubes  x 21,000 cpm x        µCi  = Required Activity (µCi)  
           1     tube  1,665,000 cpm 
 
= approx. 15 µCi/1000 RIA tubes 
 
Prepare trace at RIA working dilution of 21,000 cpm/100 µl.  This would result 
in, for example, 60 µCi 125I IGF-1 trace being diluted out to 500 ml RIA working 
stock: 
 
60 µCi   x 1,665,000 cpm x      RIA tube  x    1 ml                    = 500 ml trace   
    1             µCi            21,000 cpm      10 RIA tubes 
 
Prepare and store in an appropriately labeled HD polypropylene bottle wrapped 
with lead-foil shielding (preferably set in a vessel of greater volume for stability, 
handling safety and spill control). 
 
Survey and thaw raw trace shipment under hood.  Measure out and record 
approximately 75 % of the tracer’s expected final volume of RIA buffer. Pour 
back and hold ~10 ml of measured buffer volume.  Using this volume, and a 1 cc 
syringe w/ 20 GA needle, suspend and aspirate trace into 1.0 ml.  Carefully 
transfer this, liquid to liquid, into the storage bottle. Rinse tracer’s pig, through 
septum, with at least 5 x 1.0 ml aliquots of same buffer, transferring each to 
storage bottle using the same syringe.  Add unused buffer remainder to storage 
bottle.  Let dilution set for at least two hours before counting (n = 4) x 100 µl 
aliquots x 1 min.  Calculate the final working dilution as above.  Make final 
dilution and store, preferably overnight, before use. 
 
9.  IGF-I Standards 
Absolute range of IGF-1 standards @1:200 sample dilution is 19.54 through 
5000 ng/ml serum. (Dilutions are 1:100 at sera extraction, and 1:2 in RIA; final = 
1:200.) 
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Expected biological range should be approximately 40 to 250 ng/ml sera, 
therefore most samples should be represented by the range between the 0.98 and 
1.56 ng/ml standards. 
hIGF-1, BIO: Lot #01, sample #1168, 134 µg/vial, lyophilized. 
Source: A.F. Parlow, National Hormone and Peptide Program,  
Harbor-UCLA Medical Center, 1000 West Carson St, Torrance CA 90509 phone 
310.222.3537, email parlow@humc.edu 
 
Reconstitute lyophilized standard stock with 1.00 ml ddH2O (IGF-1 STD Stock I).  
Note: this resulted in a previous shipment of this specific standard (sample #1168) 
having a concentration of 134 µg/ml (vial’s specific mass listed on same by FJP).   
 
Construct 1 µg/ml IGF-1 STD Stock II.  Transfer 74.63 µl (i.e. 10 µg) to a 10 ml 
volumetric containing approximately 8.0 ml IGF-1 RIA buffer (liquid to liquid, 
using a Hamilton syringe). Bring to volume and allow for equilibration.  Aliquot 
and freeze if not used immediately. 
 
Prepare serial dilutions of IGF-1 standards fresh for each RIA series.   Add 625 µl 
of 1 µg /ml IGF-1 stock II to a 25 ml volumetric containing approximately 20 ml 
IGF-1 RIA buffer.  Use liquid-to-liquid transfer, and allow for equilibration.  The 
resulting STD A = 25 ng/ml.   
 
Continue preparation of serial dilutions by mass, rather than by volume.  Label (n 
= 8) 50 ml PP conical-bottom centrifuge tubes for the following array of 
standards.  Tare each tube on a three-place balance and load each with exactly 
12.00 g of IGF-1 RIA buffer. Transfer exactly 12.00 g of STD A to the STD B 
tube (12.5 ng/ml).  Mix by gentle vortexing and/or inversion, then allow to 
equilibrate for a minute or two before continuing with the next 1:1 dilution (STD 
C = 6.25 ng/ml).  Continue serial dilutions through STD I (0.098 ng/ml).  Aliquot 
each IGF-1 standard at 1.0 or 2.0 ml and freeze sets until use.  Prepare fresh for 
each RIA series. 
 
IGF-I Standards chart: 
 
 ng/ml ng/tube equivalence 
IGF-1 STD at RIA  at RIA ng/ml sera 
STD A 25.000 2.500 5000.00 
STD B 12.500 1.250 2500.00 
STD C 6.250 0.625 1250.00 
STD D 3.125 0.313 625.00 
STD E 1.563 0.156 312.50 
STD F 0.781 0.078 156.25 
STD G 0.391 0.039 78.13 
STD H 0.195 0.020 39.06 
STD I 0.098 0.010 19.53 
STD J 0.000 0.000 0.00 
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10.  IGF-1 Composite Pools for RIA: 
 
For verification of inter- and intra-RIA performance over the expected biological IGF-1 
concentration range, construct a “normal” pool and a “high” pool from a composite sub-
set of acidified serum samples. 
 
Pool (n = 30) 200 µl aliquots from a random set of acidified serum samples.  Pipette 3.00 
ml of this to a 13 x 100 mm PP culture tube (to be used for the “high” pool preparation).  
Aliquot remainder of “normal” pool at 500 µl, freeze and store until use.  
 
For the “high” pool, prepare a 100 ng/ml IGF-1 stock through a 1:10 dilution of 1 µg /ml 
IGF-1 Standard Stock II.  Pipette 20 µl of the 100 ng/ml stock into 2980 µl of the 
“normal” pool aliquot to produce the “high” pool stock (e.g. back-pipette 20 µl from the 
3.0 ml and replace).  This results in the addition of 0.667 ng/ml at RIA or, after 
accounting for the 1:200 final sample dilution following RIA, a delta at RIA of 133.3 
ng/ml. (e.g. “normal” IGF-I concentration plus 133 ng/ml at the serum level).  Vortex and 
aliquot “high” pool at 500 µl, freeze and store until use. 
 
IGF-I Assay Protocol: 
 
A.  Acidification of Samples 
1.  Pipette 10 µl of each bovine serum sample into 12X75 polypropylene culture tubes.  
(Polypropylene tubes must be used due to low pH.  Number tubes in odd numbers so that 
samples can be assayed in duplicate.) 
2.  Add 400 µl of 1M glycine to each sample. 
3.  Add 500 µl of IGF-I Assay Buffer to each sample. 
4.  Cap tubes and incubate in 37ºC water bath for 48 hours. 
5.  Add 90 µl of 0.5N NaOH to all samples and vortex to mix.  (Continue assay 
immediately.  Samples are diluted 1:100 and final calculations will need to be 
multiplied by 100.) 
 
B.  Assay Procedure 
1.    Each assay should include at least triplicate tubes of total (T), non-specific binding 
(NSB), zero tubes (B0), standards, and pools.  Single acidified samples should be 
pipetted into duplicate for the RIA. 
2.    Pipette 400 µl of IGF-I Assay Buffer into NSB tubes. 
3.    Pipette 300 µl of IGF-I Assay Buffer into B0 tubes. 
4.    Pipette 200 µl of IGF-I Assay Buffer into standard tubes. 
5.    Pipette 250 µl of IGF-I Assay Buffer into all sample tubes and pools. 
6.    Add 100 µl of each standard to each designated standard tube. 
7.    Add 50 µl of each acidified serum sample into each designated tube pair. 
8.    Add 50 µl of acidified pools into control pool tubes. 
9.    Pipette 100 µl of primary antibody to all tubes except NSB and T. 
10.  Carefully shake tubes to mix and cover with parafilm. 
11.  Incubate for 24 hours at 4ºC. 
12.  Pipette 100 µl of [125I]-IGF-I Tracer to all tubes. 
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13.  Cover tubes with parafilm and shake the tubes carefully to mix. 
14.  Incubate for 16 hours at 4ºC. 
15.  Pipette 50 µl of NRS to all tubes except totals. 
16.  Pipette 50 µl of GARGG to all tubes except totals. 
17.  Pipette 300 µl of PEG to all tubes except totals. 
18.  Carefully shake tubes to mix and cover with parafilm. 
19.  Incubate tubes at room temperature for 30 minutes. 
20.  Centrifuge tubes at 3000 rcf for 25 minutes at 4ºC. 
21.  Decant tubes (except totals) immediately into radioactive waste container. 
22.  Allow tubes to remain upside down on absorbent towels for 5 minutes. 
23.  Remove all visible droplets by tapping tube bottoms. 
24.  Count tubes on Beckman gamma counter for 1 minute per sample. 
25.  Use AssayZap to calculate concentrations of unknowns in comparison to a known 
standard curve. 
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APPENDIX H 
 
TESTOSTERONE RADIOIMMUNOASSAY (RIA) PROTOCOL 
 
1.  Thaw frozen serum or EDTA plasma samples and place on ice. 
2.  Pipet blood samples into 12X75 polypropylene tubes in duplicate. 
3.  Bring volume in each tube to 500 µl with PBSG. 
4.  Pipet 500 µl of standards in duplicate starting at 8000 pg of testosterone per tube and 
continuing to 3.9 pg per tube according to the following table.  The total, non-specific 
binding (NSB) and 0 tubes only receive PBSG buffer. 
 
Standard PBSG Buffer Sample 
Total 800 µl 0 µl 
Non-specific Binding (NSB) 600 µl 0 µl 
0 pg/tube 500 µl 0 µl 
3.9 pg/tube 0 µl 500 µl 
7.9 pg/tube 0 µl 500 µl 
15.6 pg/tube 0 µl 500 µl 
31.25 pg/tube 0 µl 500 µl 
62.5 pg/tube 0 µl 500 µl 
125 pg/tube 0 µl 500 µl 
250 pg/tube 0 µl 500 µl 
500 pg/tube 0 µl 500 µl 
1000 pg/tube 0 µl 500 µl 
2000 pg/tube 0 µl 500 µl 
4000 pg/tube 0 µl 500 µl 
8000pg/tube 0 µl 500 µl 
 
5.  Add 100 µl of testosterone antibody (Colorado State University) to each tube except 
for the total and NSB tubes. 
6.  Add 100 µl of 3H-testosterone tracer (Perkin Elmer-NEN, Boston, MA) to all tubes. 
7.  Mix the tubes gently by shaking and cover with foil.  Incubate at 4°C for 16-20 hours. 
8.  Add 200 µl of charcoal solution to each tube except for the total tubes. 
9.  Vortex the tubes and incubate at 4°C for 15 minutes. 
10. Centrifuge samples at 2000xg for 20 minutes. 
11. Pour samples into scintillation tubes containing 5 ml of Ecolume biodegradeable 
scintillation cocktail (MP Biomedicals, Irvine, CA).  Cap the tubes and shake them 
gently. 
12. Count the samples for 1 minute each using a Beckman Beta counter. 
13. Use AssayZap to calculate concentrations of unknowns in comparison to a known 
standard curve. 
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Reagents: 
 
1.  0.01 M Phosphate Buffered Saline with 0.1% gel (PBSG) 
 8.17 g Sodium Chloride 
 0.856 g Sodium Phosphate monobasic (NaH2PO4H2O) 
 0.54 g Sodium Phosphate dibasic (Na2HPO4) 
 3.72 g Ethylenediaminetetra acetic acid (EDTA) 
 0.1 g Thimerosal powder (merthiolate) 
 
Dissolve above components in 900 ml of double-distilled water.  Adjust pH to 
7.0.  Bring volume up to 1 liter with water.  Add 1 g of gelatin and heat and stir 
on low for 2 hours.  Cool and store at 4°C. 
 
2.  Charcoal 
 3.125 g Charcoal 
 0.3125 g Dextran Pharmacia T-70 
Add above components to 500 ml PBSG and stir at low speed overnight at 4°C to 
bring into solution.  Stir charcoal for 30 minutes before each use. 
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APPENDIX I 
 
IN VITRO TESTIS CULTURE 
 
1.  Collect stallion testicular parenchyma at the Veterinary Large Animal Medicine 
(VLAM) facilities and place in aseptic bags on ice. 
2.  Trim and weigh out 1 gram pieces of testicular parenchyma. 
3.  Transfer 1 gram of tissue into a 50-ml polypropylene tube containing 5 ml of DMEM 
media with Penicillin/Streptomycin. 
4.  Put each tube into a shaking water bath uncovered and when all tubes are in the water 
bath, cover the water bath with a lid as air tight as possible. 
5.  Incubate samples at 34°C with 95% O2/5% CO2 exposure for two hours. 
6.  Remove media and freeze at –20°C in appropriately labeled baseline 12X75 
polypropylene tubes. 
7.  Add 5 ml treatments of either media alone, 10 units hCG, 100 units hCG, 10-5 M 
Forskolin or 1 mg/ml cyclic AMP to the testis tissue.  Incubate for another two hours 
in the same conditions as before. 
8.  After two hours, the samples are divided into either 2-hr or 4-hr treatment groups.  
Media from the 2-hr treatment group is collected and frozen at –20°C.  The testis 
samples are removed and frozen at –80°C in RNase-free tubes.  Remove 200 µl of 
media from the 4-hr incubation samples and freeze.  Continue the incubation for two 
more hours. 
9.  Remove the media from the 4-hr incubation samples and freeze at –20°C.  Transfer 
the testis samples to RNase-free tubes and freeze at –80°C. 
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APPENDIX J 
 
WESTERN BLOT PROCEDURE FOR StAR AND P450SCC PROTEINS 
 
 
Solutions: 
A.  Acrylamide/Bis-acrylamide 
 87.6 g acrylamide (29.2 g/100 ml; Kodak cat# 5521) 
 2.4 g N,N’-bis-methylene-acrylamide (0.8 g/100 ml; Sigma cat# M-2022) 
 Make to 300 ml with distilled water.  Filter and store at 4°C in the dark. 
 
B.  1.5 M Tris-HCl, pH 8.8 
 27.23 g trizma base (Sigma cat# T-1503) 
Mix in distilled water and adjust pH to 8.8 with 1N HCl.  Make to 100 ml with 
distilled water. 
 
C.  0.5 M Tris-HCl, pH 6.8 
 6 g trizma base (Sigma cat# T-1503) 
Mix in distilled water and adjust pH to 6.8 with 1N HCl.  Make to 100 ml with 
distilled water and store at 4°C. 
 
D.  10% SDS 
Dissolve 10 g sodium dodecyl sulfate (Sigma cat# L-4390) in distilled water with 
gentle stirring.  Bring volume to 100 ml with distilled water. 
 
E.  Sample Buffer 
 Distilled water      4.0 ml 
 0.5 M tris-HCl, pH 6.8     1.0 ml 
 glycerol (EM Science cat# GX0185-6)   0.8 ml 
 10% (w/v) SDS      1.6 ml 
 2-mercaptoethanol (Sigma M-3148)    0.4 ml 
 0.05% (w/v) bromophenol blue (JT Baker D293-01) 0.2 ml 
 
Mix the above ingredients and store at room temperature.  Dilute samples 1:4 with 
sample buffer and heat at 95°C for 10 minutes before loading gel. 
 
F.  5X Electrode (Running) Buffer, pH 8.3 
 9 g trizma base (Sigma cat# T-1503) 
 43.2 g glycine (Sigma cat# G-7126) 
 3 g sodium dodecyl sulfate (Sigma cat# L-4390) 
 
Mix and bring to 600 ml with distilled water.  Store at 4°C.  Warm to 37°C if 
precipitation occurs.  Dilute 60 ml 5X stock buffer with 240 ml distilled water for 
use. 
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G.  Lower Tris, pH 8.8 
 18.15 g trizma base (Sigma cat# T-1503) 
 4 ml 10% SDS 
Mix in distilled water.  Adjust pH to 8.8 and bring to 100 ml with distilled water.  
Filter solution. 
 
H.  Upper Tris, pH 6.8 
 6 g trizma base (Sigma cat# T-1503) 
 4 ml 10% SDS 
Mix in distilled water.  Adjust pH to 6.8 and bring volume to 100 ml with distilled 
water.  Filter solution. 
 
I.  Tris-Sucrose-EDTA Buffer 
 0.607 g trizma base (Sigma cat# T-1503) 
 42.79 g sucrose (Sigma cat# S-0389) 
 0.145 g EDTA (Ethylenediaminetetra acetic acid; Sigma cat# E-5134) 
Mix ingredients in distilled water.  Adjust pH to 7.4 and bring volume to 500 ml 
in distilled water. 
 
J.  10% Ammonium Persulfate 
Mix 1.5 g ammonium persulfate (Sigma cat# A-9164) in 15 ml distilled water by 
inversion.  Good for one month maximum, store at 4°C. 
 
K.  Mini Gel (12.5%; for 2 gels) 
 7.5 ml acrylamide/bisacrylamide 
 4.5 ml lower tris 
 6 ml distilled water 
 75 µl 10% ammonium persulfate 
 15 µl temed 
 
L.  Mini Gel Stacker (3%; for 2 gels) 
 450 µl acrylamide/bisacrylamide 
 1125 µl upper tris 
 2.88 ml distilled water 
 37.5 µl 10% ammonium persulfate 
 15 µl temed 
 
M.  Transfer Buffer 
 2.42 g trizma base (Sigma cat# T-1503) 
 11.24 g glycine (Sigma cat# G-7126) 
 100 ml methanol (Sigma cat# M-3641) 
 0.1 g sodium dodecyl sulfate (Sigma cat# L-4390) 
 Mix and bring to 1 liter with distilled water. 
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N.  PBS + 0.25% TWEEN Buffer 
 8 g sodium chloride (NaCl; EM Science cat# 7710) 
 0.2 g potassium chloride (KCl; Fisher Scientific cat# P-217) 
 1.44 g sodium phosphate dibasic (Na2HPO4; Fisher Scientific cat# S-374) 
 0.24 g potassium phosphate monobasic (KH2PO4; EM Science cat# PX1565-1) 
Mix and bring to 1 liter with distilled water.  Add 2.5 ml TWEEN-20 
(polyoxyethylene-sorbitan monolaurate; Sigma cat# P-1379). 
 
O.  Blocking Buffer (4%) 
 Mix 4 g carnation powdered milk in 100 ml PBS + Tween Buffer. 
 
P.  Stripping Buffer 
 2 g sodium dodecyl sulfate (Sigma cat# L-4390) 
 0.757 g trizma base (Sigma cat# T-1503) 
 700 µl 2-mercaptoethanol (Sigma cat# M-3148) 
Mix in distilled water.  Adjust pH to 6.8 and bring volume to 100 ml with distilled 
water. 
 
Q.  Strip Wash Buffer 
 0.12 g trizma base (Sigma cat# T-1503) 
 0.876 g sodium chloride (NaCl; EM Science cat# 7710) 
Mix in distilled water.  Adjust pH to 7.4 and bring volume to 100 ml with distilled 
water. 
 
 
Western Blot Procedures: 
 
A.  Protein Isolation 
1.  Trim 200 mg of frozen tissue and place in Tris-Sucrose-EDTA buffer in a 50-ml tube 
(ex:  0.2 g in 2 ml buffer). 
2.  Homogenize samples for 30 seconds each two times. 
3.  Centrifuge the homogenized samples at 600xg for 15 minutes. 
4.  Remove the supernatant and transfer to a 2-ml microfuge tube. 
5.  Centrifuge at 12,000 rpm for 15 minutes. 
6.  Resuspend the pellet in 0.5 ml Tris-Sucrose-EDTA buffer. 
 
B. Protein Assay 
1.  In a separate microfuge tube, dilute the samples 1:10 with water. 
2.  Dilute 4 µl BSA in 196 µl water and pipette 0, 2, 3, 4, 5, 7.5, 10, 12.5, 15, 17.5, and 
20 µl in duplicate in a 96-well plate.  (Concentrations = 0, 0.4, 0.6, 0.8, 1.0, 1.5, 2.0, 
2.5, 3.0, 3.5 and 4.0 µg) 
3.  Pipette 3 µl of each diluted sample in duplicate in the same 96-well plate. 
4.  Add 200 µl of Bradford Reagent diluted 1:5 in water. 
5.  Allow the samples to incubate at room temperature for 10 minutes. 
6.  Read the plate at Optical Density (OD) 562 to obtain absorbance values for each 
sample with a plate reader and calculate sample concentrations. 
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7.  Centrifuge samples (from #6) at 12,000 rpm for 15 minutes. 
8.  Pour off supernatant and freeze samples at –80°C until ready to run gel. 
 
C.  Gel Preparation 
1.  Pour polyacrylamide gel according to recipe above pouring the lower portion without 
air bubbles and stopping at the bottom of where the comb will be.  Overlay water on 
top of the gel while it polymerizes to keep the gel from drying out.  Pour off water 
and dry with 3 mm whatman paper before pouring stacker gel on top.  Stacker gel 
should be poured with the 10-well comb in place without air bubbles and allowed to 
polymerize. 
2.  Resuspend samples in sample loading buffer at a concentration of 4 µg/µl. 
3.  Resuspend lyophilized MA-10 marker (500 µg) in 500 µl sample loading buffer and 
use 5 µl per gel. 
4.  Load 5-7 µl of pre-stained molecular weight marker (cat# 161-0305; Bio-Rad, 
Hercules, CA). 
5.  Run the gel at 4°C in 1X Electrode Buffer for 30 minutes at 200 volts. 
6.  Remove the gel and notch at well 1. 
7.  Place the gel in cold Transfer Buffer for 5 minutes. 
8.  Cut two pieces of 3 mm Whatman paper to the same size as the sponge. 
9.  Cut the PVDF membrane (cat# 162-0184; Bio-Rad, Hercules, CA) to the same size as 
the gel. 
10. Wet the membrane in methanol, soak it in water until saturated, then place the 
membrane in transfer buffer. 
11. Set up the transfer apparatus using the following explanation (all items should be 
soaking in transfer buffer): 
 YOU   
Plastic grid (clear side of mini-gel) 
   Sponge pad 
   3mm Whatman paper 
   PVDF membrane 
   Gel (back-side facing up) 
   3mm Whatman paper 
   Sponge pad 
   Plastic grid (black side of mini-gel) 
 LAB BENCH 
**Make sure there are no air bubbles between the gel, PVDF membrane and the 
Whatman paper. 
12. Place the plastic grids in the transfer apparatus where the gel is on the black side and 
the membrane is on the red side.  Fill the transfer apparatus with cold transfer buffer 
and a frozen ice pack in order to keep overheating from taking place. 
13. Run at 100 volts for 2 hours.  The transfer apparatus may have to sit in a bucket of ice 
to keep the buffer cool. 
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D.  Membrane Preparation 
1.  Soak the membrane in Blocking Buffer while shaking at 4°C for 1 hour or overnight. 
2.  Make primary antibody in 2% milk solution at 1:1000 dilution. 
3.  Remove the blocking buffer and shake the membrane in primary antibody for 1 hour 
at room temperature (StAR antibody-Dr. Stocco, Texas Tech University, TX; 
P450scc antibody-Chemicon, Temecula, CA). 
4.  Remove the primary antibody solution and save it at 4°C (can be used twice). 
5.  Wash the membrane with PBS + Tween Buffer 3 times for 5 minutes each (shake). 
6.  Pour off wash buffer and shake the membrane in secondary antibody for 30 minutes at 
room temperature (cat# NA 934; Amersham Pharmacia, Piscataway, NJ; 1:15,000 
dilution—3.3 µl in 50 ml 2% milk solution). 
7.  Remove the secondary antibody solution and save at 4°C (can be used twice). 
8.  Wash the membrane with PBS + Tween Buffer 2 times for 30 minutes each (shake). 
9.  Remove the membrane and expose protein side to chemiluminescence reagent (NEN 
cat# NEL-102) for 1 minute (5 ml of each mixed). 
10. Place the membrane in sheet protector or saran™ wrap and expose to film 
immediately (Hyperfilm MP from Amersham Biosciences, Piscataway, NJ; cat# RPN 
1678H). 
11. Membranes can be stored moist at 4ºC in a Ziploc bag for 1 month. 
 
E.  Stripping and Re-blotting Westerns 
1.  Soak the membrane in strip buffer for 30 minutes at 70°C, shaking every 10 minutes. 
2.  Wash the membrane in wash buffer 2 times for 10 minutes each at room temperature 
(shake). 
3.  Rinse the membrane with PBS + Tween Buffer for 5 minutes. 
4.  Block the membrane with Blocking Buffer as before and proceed with antibody 
staining procedures above. 
 
*If you are restaining with the same antibody, strip the membrane using 0.1 M 
Glycine, pH 2.6 for 5-10 minutes at room temperature.  Rinse with PBS + Tween 
Buffer, block and restain membrane as before. 
 
**If the membrane has dried out considerably, wet the membrane very quickly in 
methanol and then begin soaking in strip buffer. 
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